1
|
Ballout N, Boullier A, Darwiche W, Ait-Mohand K, Trécherel E, Gallégo T, Gomila C, Yaker L, Gennero I, Kovensky J, Ausseil J, Toumieux S. DP2, a Carbohydrate Derivative, Enhances In Vitro Osteoblast Mineralisation. Pharmaceuticals (Basel) 2023; 16:1512. [PMID: 38004380 PMCID: PMC10674337 DOI: 10.3390/ph16111512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2023] [Revised: 10/14/2023] [Accepted: 10/17/2023] [Indexed: 11/26/2023] Open
Abstract
Bone fracture healing is a complex biological process involving four phases coordinated over time: hematoma formation, granulation tissue formation, bony callus formation, and bone remodelling. Bone fractures represent a significant health problem, particularly among the elderly population and patients with comorbidities. Therapeutic strategies proposed to treat such fractures include the use of autografts, allografts, and tissue engineering strategies. It has been shown that bone morphogenetic protein 2 (BMP-2) has a therapeutic potential to enhance fracture healing. Despite the clinical efficacy of BMP-2 in osteoinduction and bone repair, adverse side effects and complications have been reported. Therefore, in this in vitro study, we propose the use of a disaccharide compound (DP2) to improve the mineralisation process. We first evaluated the effect of DP2 on primary human osteoblasts (HOb), and then investigated the mechanisms involved. Our findings showed that (i) DP2 improved osteoblast differentiation by inducing alkaline phosphatase activity, osteopontin, and osteocalcin expression; (ii) DP2 induced earlier in vitro mineralisation in HOb cells compared to BMP-2 mainly by earlier activation of Runx2; and (iii) DP2 is internalized in HOb cells and activates the protein kinase C signalling pathway. Consequently, DP2 is a potential therapeutical candidate molecule for bone fracture repair.
Collapse
Affiliation(s)
- Nissrine Ballout
- Société d’Accélération du Transfert de Technologie-Nord, 59800 Lille, France; (N.B.)
- Institut Toulousain des Maladies Infectieuses et Inflammatoires, INSERM UMR1291, CNRS UMR5051, University of Toulouse III, 31024 Toulouse, France
- Service de Biochimie, Institut Fédératif de Biologie, CHU Toulouse, 31024 Toulouse, France
| | - Agnès Boullier
- Mécanismes Physiopathologiques et Conséquences des Calcifications Cardiovasculaires, UR7517, Centre Universitaire de Recherche en Santé, CURS-UPJV, University of Picardy Jules Verne, 80054 Amiens, France (E.T.)
- Laboratory of Biochemistry, CHU Amiens-Picardie, 80054 Amiens, France
| | - Walaa Darwiche
- Société d’Accélération du Transfert de Technologie-Nord, 59800 Lille, France; (N.B.)
| | - Katia Ait-Mohand
- Laboratoire de Glycochimie et des Agroressources d’Amiens, UR 7378, CNRS, Université de Picardie Jules Verne, 80039 Amiens, France
| | - Eric Trécherel
- Mécanismes Physiopathologiques et Conséquences des Calcifications Cardiovasculaires, UR7517, Centre Universitaire de Recherche en Santé, CURS-UPJV, University of Picardy Jules Verne, 80054 Amiens, France (E.T.)
| | - Théo Gallégo
- Société d’Accélération du Transfert de Technologie-Nord, 59800 Lille, France; (N.B.)
| | - Cathy Gomila
- Mécanismes Physiopathologiques et Conséquences des Calcifications Cardiovasculaires, UR7517, Centre Universitaire de Recherche en Santé, CURS-UPJV, University of Picardy Jules Verne, 80054 Amiens, France (E.T.)
| | - Linda Yaker
- Mécanismes Physiopathologiques et Conséquences des Calcifications Cardiovasculaires, UR7517, Centre Universitaire de Recherche en Santé, CURS-UPJV, University of Picardy Jules Verne, 80054 Amiens, France (E.T.)
| | - Isabelle Gennero
- Institut Toulousain des Maladies Infectieuses et Inflammatoires, INSERM UMR1291, CNRS UMR5051, University of Toulouse III, 31024 Toulouse, France
- Service de Biochimie, Institut Fédératif de Biologie, CHU Toulouse, 31024 Toulouse, France
| | - José Kovensky
- Laboratoire de Glycochimie et des Agroressources d’Amiens, UR 7378, CNRS, Université de Picardie Jules Verne, 80039 Amiens, France
| | - Jérôme Ausseil
- Institut Toulousain des Maladies Infectieuses et Inflammatoires, INSERM UMR1291, CNRS UMR5051, University of Toulouse III, 31024 Toulouse, France
- Service de Biochimie, Institut Fédératif de Biologie, CHU Toulouse, 31024 Toulouse, France
| | - Sylvestre Toumieux
- Laboratoire de Glycochimie et des Agroressources d’Amiens, UR 7378, CNRS, Université de Picardie Jules Verne, 80039 Amiens, France
| |
Collapse
|
2
|
Yaker L, Tebani A, Lesueur C, Dias C, Jung V, Bekri S, Guerrera IC, Kamel S, Ausseil J, Boullier A. Extracellular Vesicles From LPS-Treated Macrophages Aggravate Smooth Muscle Cell Calcification by Propagating Inflammation and Oxidative Stress. Front Cell Dev Biol 2022; 10:823450. [PMID: 35356285 PMCID: PMC8959646 DOI: 10.3389/fcell.2022.823450] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2021] [Accepted: 02/09/2022] [Indexed: 12/29/2022] Open
Abstract
Background: Vascular calcification (VC) is a cardiovascular complication associated with a high mortality rate among patients with diseases such as atherosclerosis and chronic kidney disease. During VC, vascular smooth muscle cells (VSMCs) undergo an osteogenic switch and secrete a heterogeneous population of extracellular vesicles (EVs). Recent studies have shown involvement of EVs in the inflammation and oxidative stress observed in VC. We aimed to decipher the role and mechanism of action of macrophage-derived EVs in the propagation of inflammation and oxidative stress on VSMCs during VC. Methods: The macrophage murine cell line RAW 264.7 treated with lipopolysaccharide (LPS-EK) was used as a cellular model for inflammatory and oxidative stress. EVs secreted by these macrophages were collected by ultracentrifugation and characterized by transmission electron microscopy, cryo-electron microscopy, nanoparticle tracking analysis, and the analysis of acetylcholinesterase activity, as well as that of CD9 and CD81 protein expression by western blotting. These EVs were added to a murine VSMC cell line (MOVAS-1) under calcifying conditions (4 mM Pi—7 or 14 days) and calcification assessed by the o-cresolphthalein calcium assay. EV protein content was analyzed in a proteomic study and EV cytokine content assessed using an MSD multiplex immunoassay. Results: LPS-EK significantly decreased macrophage EV biogenesis. A 24-h treatment of VSMCs with these EVs induced both inflammatory and oxidative responses. LPS-EK-treated macrophage-derived EVs were enriched for pro-inflammatory cytokines and CAD, PAI-1, and Saa3 proteins, three molecules involved in inflammation, oxidative stress, and VC. Under calcifying conditions, these EVs significantly increase the calcification of VSMCs by increasing osteogenic markers and decreasing contractile marker expression. Conclusion: Our results show that EVs derived from LPS-EK–treated-macrophages are able to induce pro-inflammatory and pro-oxidative responses in surrounding cells, such as VSMCs, thus aggravating the VC process.
Collapse
Affiliation(s)
- Linda Yaker
- MP3CV-UR7517, CURS-University of Picardie Jules Verne, Amiens, France
| | - Abdellah Tebani
- INSERM U1245, CHU Rouen, Normandie University, UNIROUEN, Rouen, France
- Department of Metabolic Biochemistry, Rouen University Hospital, Rouen, France
| | - Céline Lesueur
- INSERM U1245, CHU Rouen, Normandie University, UNIROUEN, Rouen, France
| | - Chloé Dias
- Infinity, INSERM UMR1291, CNRS UMR5051, University of Toulouse III, Toulouse, France
| | - Vincent Jung
- INSERM US24/CNRS UAR3633, Proteomic Platform Necker, University of Paris—Federative Research Structure Necker, Paris, France
| | - Soumeya Bekri
- INSERM U1245, CHU Rouen, Normandie University, UNIROUEN, Rouen, France
- Department of Metabolic Biochemistry, Rouen University Hospital, Rouen, France
| | - Ida Chiara Guerrera
- INSERM US24/CNRS UAR3633, Proteomic Platform Necker, University of Paris—Federative Research Structure Necker, Paris, France
| | - Saïd Kamel
- MP3CV-UR7517, CURS-University of Picardie Jules Verne, Amiens, France
- Laboratory of Biochemistry, CHU Amiens-Picardie, Amiens, France
| | - Jérôme Ausseil
- Infinity, INSERM UMR1291, CNRS UMR5051, University of Toulouse III, Toulouse, France
- Service de Biochimie, Institut Fédératif de Biologie, CHU Toulouse, Toulouse, France
| | - Agnès Boullier
- MP3CV-UR7517, CURS-University of Picardie Jules Verne, Amiens, France
- Laboratory of Biochemistry, CHU Amiens-Picardie, Amiens, France
- *Correspondence: Agnès Boullier,
| |
Collapse
|
3
|
Bergamelli M, Martin H, Bénard M, Ausseil J, Mansuy JM, Hurbain I, Mouysset M, Groussolles M, Cartron G, Tanguy le Gac Y, Moinard N, Suberbielle E, Izopet J, Tscherning C, Raposo G, Gonzalez-Dunia D, D'Angelo G, Malnou CE. Human Cytomegalovirus Infection Changes the Pattern of Surface Markers of Small Extracellular Vesicles Isolated From First Trimester Placental Long-Term Histocultures. Front Cell Dev Biol 2021; 9:689122. [PMID: 34568315 PMCID: PMC8461063 DOI: 10.3389/fcell.2021.689122] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Accepted: 07/28/2021] [Indexed: 12/12/2022] Open
Abstract
Extracellular vesicles (EVs) have increasingly been recognized as key players in a wide variety of physiological and pathological contexts, including during pregnancy. Notably, EVs appear both as possible biomarkers and as mediators involved in the communication of the placenta with the maternal and fetal sides. A better understanding of the physiological and pathological roles of EVs strongly depends on the development of adequate and reliable study models, specifically at the beginning of pregnancy where many adverse pregnancy outcomes have their origin. In this study, we describe the isolation of small EVs from a histoculture model of first trimester placental explants in normal conditions as well as upon infection by human cytomegalovirus. Using bead-based multiplex cytometry and electron microscopy combined with biochemical approaches, we characterized these small EVs and defined their associated markers and ultrastructure. We observed that infection led to changes in the expression level of several surface markers, without affecting the secretion and integrity of small EVs. Our findings lay the foundation for studying the functional role of EVs during early pregnancy, along with the identification of new predictive biomarkers for the severity and outcome of this congenital infection, which are still sorely lacking.
Collapse
Affiliation(s)
- Mathilde Bergamelli
- Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM, CNRS, UPS, Université de Toulouse, Toulouse, France
| | - Hélène Martin
- Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM, CNRS, UPS, Université de Toulouse, Toulouse, France
| | - Mélinda Bénard
- Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM, CNRS, UPS, Université de Toulouse, Toulouse, France.,Service de Néonatalogie, CHU Toulouse, Hôpital des Enfants, Toulouse, France
| | - Jérôme Ausseil
- Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM, CNRS, UPS, Université de Toulouse, Toulouse, France.,Laboratoire de Biochimie, CHU Toulouse, Hôpital Rangueil, Toulouse, France
| | - Jean-Michel Mansuy
- Laboratoire de Virologie, CHU Toulouse, Hôpital Purpan, Toulouse, France
| | - Ilse Hurbain
- CNRS UMR 144, Structure et Compartiments Membranaires, Institut Curie, Université Paris Sciences et Lettres, Paris, France.,CNRS UMR 144, Plateforme d'Imagerie Cellulaire et Tissulaire (PICT-IBiSA), Institut Curie, Université Paris Sciences et Lettres, Paris, France
| | - Maïlys Mouysset
- Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM, CNRS, UPS, Université de Toulouse, Toulouse, France
| | - Marion Groussolles
- Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM, CNRS, UPS, Université de Toulouse, Toulouse, France.,Service de Diagnostic Prénatal, CHU Toulouse, Hôpital Paule de Viguier, Toulouse, France.,INSERM UMR 1027, UPS, Equipe SPHERE Epidémiologie et Analyses en Santé Publique: Risques, Maladies Chroniques et Handicaps, Université de Toulouse, Toulouse, France
| | - Géraldine Cartron
- Service de Gynécologie Obstétrique, CHU Toulouse, Hôpital Paule de Viguier, Toulouse, France
| | - Yann Tanguy le Gac
- Service de Gynécologie Obstétrique, CHU Toulouse, Hôpital Paule de Viguier, Toulouse, France
| | - Nathalie Moinard
- Développement Embryonnaire, Fertilité, Environnement (DEFE), INSERM UMR 1203, Université de Toulouse et Université de Montpellier, Montpellier, France.,CECOS, Groupe d'Activité de Médecine de la Reproduction, CHU Toulouse, Hôpital Paule de Viguier, Toulouse, France
| | - Elsa Suberbielle
- Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM, CNRS, UPS, Université de Toulouse, Toulouse, France
| | - Jacques Izopet
- Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM, CNRS, UPS, Université de Toulouse, Toulouse, France.,Laboratoire de Virologie, CHU Toulouse, Hôpital Purpan, Toulouse, France
| | - Charlotte Tscherning
- Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM, CNRS, UPS, Université de Toulouse, Toulouse, France
| | - Graça Raposo
- CNRS UMR 144, Structure et Compartiments Membranaires, Institut Curie, Université Paris Sciences et Lettres, Paris, France.,CNRS UMR 144, Plateforme d'Imagerie Cellulaire et Tissulaire (PICT-IBiSA), Institut Curie, Université Paris Sciences et Lettres, Paris, France
| | - Daniel Gonzalez-Dunia
- Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM, CNRS, UPS, Université de Toulouse, Toulouse, France
| | - Gisela D'Angelo
- CNRS UMR 144, Structure et Compartiments Membranaires, Institut Curie, Université Paris Sciences et Lettres, Paris, France
| | - Cécile E Malnou
- Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM, CNRS, UPS, Université de Toulouse, Toulouse, France
| |
Collapse
|
4
|
Deiva K, Ausseil J, de Bournonville S, Zérah M, Husson B, Gougeon ML, Poirier-Beaudouin B, Zafeiriou D, Parenti G, Heard JM, Tardieu M. Intracerebral Gene Therapy in Four Children with Sanfilippo B Syndrome: 5.5-Year Follow-Up Results. Hum Gene Ther 2021; 32:1251-1259. [PMID: 34405688 DOI: 10.1089/hum.2021.135] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
We report the safety (primary endpoint) and efficacy (secondary endpoint) of a novel intracerebral gene therapy at 5.5 years of follow-up in children with Sanfilippo B. An uncontrolled, phase 1/2 clinical trial was performed in four patients aged 20, 26, 30, and 53 months. Treatment consisted of 16 intracerebral and cerebellar deposits of a recombinant adeno-associated viral vector encoding human α-N-acetylglucosaminidase (rAAV2/5-hNAGLU) plus immunosuppression. An intermediate report at 30 months was previously published. Thirty treatment-emergent adverse events were reported between 30 and 66 months after surgery, including three classified as severe with no serious drug reactions. At 5.5 years, NAGLU activity was persistently detected in the lumbar cerebrospinal fluid (18% of unaffected control level). Circulating T cells reacting against NAGLU peptides were present, indicating a lack of acquired tolerance. Patients 2, 3, and 4 showed progressive brain atrophy and neurocognitive evolution that did not differ from untreated Sanfilippo A/B children. Patient 1, enrolled at 20 months of age, had a milder disease with normal brain imaging and a significantly better cognitive outcome than the three other patients and untreated patients, although not equivalent to normal children. After 5.5 years, the primary endpoint of this study was achieved with a good safety profile of the proposed treatment. We have also observed sustained enzyme production in the brain and absence of immunological tolerance. Cognitive benefit was not confirmed in the three oldest patients. Milder disease in the youngest patient supports further investigations of adeno-associated vector-mediated intracerebral gene therapy in Sanfilippo B.
Collapse
Affiliation(s)
- Kumaran Deiva
- Pediatric Neurology Department, Université Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Saclay, Site Bicêtre, Le Kremlin-Bicêtre, France
| | - Jérôme Ausseil
- Service de Biochimie, Institut Fédératif de Biologie, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.,Inserm U1043 Centre de Physiopathologie de Toulouse-Purpan Université Toulouse III Paul Sabatier, Toulouse, France
| | - Stéphanie de Bournonville
- Pediatric Neurology Department, Université Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Saclay, Site Bicêtre, Le Kremlin-Bicêtre, France
| | - Michel Zérah
- Pediatric Neurosurgery Department, Assistance Publique-Hôpitaux de Paris, Hôpital Necker, Paris, France.,Institut Imagine, Université René Descartes, Paris, France.,NeuroGenCell, Institut du Cerveau et de la Moelle, Paris, France
| | - Béatrice Husson
- Pediatric Radiology Department, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Saclay, Le Kremlin-Bicêtre, France
| | - Marie-Lise Gougeon
- Innate Immunity and Viruses Unit, Global Health Department, Institut Pasteur, Paris, France
| | | | | | - Giancarlo Parenti
- Department of Translational Medical Sciences, Frederico II University, Naples, Italy.,Telethon Institute of Genetics and Medicine, Pozzuoli, Italy
| | - Jean-Michel Heard
- Department of Neuroscience, Biotherapy and Neurodegenerative Diseases Unit, Institut Pasteur, INSERM U1115, Paris, France
| | - Marc Tardieu
- Pediatric Neurology Department, Université Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris-Saclay, Site Bicêtre, Le Kremlin-Bicêtre, France
| |
Collapse
|
5
|
Touati G, Gorce M, Oliver-Petit I, Broué P, Ausseil J. [New Inborn Errors of Metabolism added in the French program of neonatal screening]. Med Sci (Paris) 2021; 37:507-518. [PMID: 34003097 DOI: 10.1051/medsci/2021057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Inborn Errors of Metabolism (IEM) are rare and heterogenous disorders. For most IEMs, clinical signs are non-specific or belated. Late diagnosis is frequent, leading to death or severe sequelae. Some IEM induce intermediate metabolites circulating in the blood. They may be detected by tandem mass spectrometry. This method allows the simultaneous detection of many IEM in different metabolic pathways. In France, newborn screening (NBS) program for IEM, limited to phenylketonuria for decades, has been recently extended to medium chain acyl-CoA dehydrogenase deficiency. Rationale, methodology and organization of this new NBS program are described. Seven other IEM (maple syrup urine disease, homocystinuria, tyrosinemia type I, glutaric aciduria type I, isovaleric acidemia, long chain hydroxy-acyl-CoA dehydrogenase deficiency, carnitine uptake disorder) should be screened in the next program extension. Efforts are needed to fully understand the predictive value of each abnormal testing at birth, decrease the false positive rate, and develop the adequate management strategies.
Collapse
Affiliation(s)
- Guy Touati
- Centre de référence en maladies héréditaires du métabolisme, Hôpital des enfants, 330 avenue de Grande-Bretagne, 31059 Toulouse Cedex 9, France
| | - Magali Gorce
- Centre de référence en maladies héréditaires du métabolisme, Hôpital des enfants, 330 avenue de Grande-Bretagne, 31059 Toulouse Cedex 9, France
| | - Isabelle Oliver-Petit
- Centre régional de dépistage néonatal. Groupe hospitalier Purpan, 330 avenue de Grande-Bretagne, 31059 Toulouse Cedex 9, France
| | - Pierre Broué
- Centre de référence en maladies héréditaires du métabolisme, Hôpital des enfants, 330 avenue de Grande-Bretagne, 31059 Toulouse Cedex 9, France
| | - Jérôme Ausseil
- Infinity, Inserm UMR1291, CNRS UMR5051, Université de Toulouse III, 31000 Toulouse, France. - Centre régional de dépistage néonatal, Institut fédératif de biologie, Groupe hospitalier Purpan, 330 avenue de Grande-Bretagne, 31059 Toulouse Cedex 9, France
| |
Collapse
|
6
|
Haseloff RF, Trudel S, Birke R, Schümann M, Krause E, Gomila C, Heard JM, Blasig IE, Ausseil J. Surrogate Cerebrospinal Fluid Biomarkers for Assessing the Efficacy of Gene Therapy in Hurler Syndrome. Front Neurol 2021; 12:640547. [PMID: 34054689 PMCID: PMC8155356 DOI: 10.3389/fneur.2021.640547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2021] [Accepted: 03/31/2021] [Indexed: 11/16/2022] Open
Abstract
Mucopolysaccharidosis type I (MPS I) is caused by a deficiency of the lysosomal hydroxylase alpha-l-iduronidase (IDUA). The resulting accumulation of dermatan and heparan sulfate induces intellectual disabilities and pre-mature death, and only a few treatment options are available. In a previous study, we demonstrated the feasibility, safety, and efficacy of gene therapy by injecting recombinant adeno-associated viral vector serotype (AAV)2/5-IDUA into the brain of a canine model of MPS I. We report on a quantitative proteomic analysis of control dogs and untreated dogs with MPS I cerebrospinal fluid (CSF) that had been collected throughout the study in the MPS I dogs. Mass spectrometry (MS) analysis identified numerous proteins present at altered levels in MPS I CSF samples. Quantitative immunoblotting, performed on CSF from healthy controls, untreated MPS I dogs, and MPS I dogs early treated and late treated by gene therapy, confirmed the MS data for a subset of proteins with higher abundance (neuronal pentraxin 1, chitinase 3-like 1, monocyte differentiation antigen CD14, and insulin-like growth factor-binding protein 2). Scoring of the results shows that the expression levels of these proteins are close to those of the control group for dogs that underwent gene therapy early in life but not for older treated animals. Our results disclose four novel predictive biomarker candidates that might be valuable in monitoring the course of the neurological disease in MPS patients at diagnosis, during clinical follow-up, and after treatment.
Collapse
Affiliation(s)
- Reiner F Haseloff
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin, Germany
| | - Stephanie Trudel
- INSERM U1043, Centre de Physiopathologie de Toulouse-Purpan, Université Toulouse III Paul Sabatier, Toulouse, France.,Service de Biochimie, Institut Fédératif de Biologie, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Ramona Birke
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin, Germany
| | - Michael Schümann
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin, Germany
| | - Eberhard Krause
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin, Germany
| | - Cathy Gomila
- INSERM U1088, Centre Universitaire de Recherche en Santé, Université de Picardie Jules Verne, Amiens, France
| | | | - Ingolf E Blasig
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin, Germany
| | - Jérôme Ausseil
- INSERM U1043, Centre de Physiopathologie de Toulouse-Purpan, Université Toulouse III Paul Sabatier, Toulouse, France.,Service de Biochimie, Institut Fédératif de Biologie, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| |
Collapse
|
7
|
Naïtaleb R, Denys A, Allain F, Ausseil J, Toumieux S, Kovensky J. Synthesis of new sulfated disaccharides for the modulation of TLR4-dependent inflammation. Org Biomol Chem 2021; 19:4346-4351. [PMID: 33908564 DOI: 10.1039/d1ob00692d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Natural sulfated glycans are key players in inflammation through TLR4 activation; therefore synthetic exogenous sulfated saccharides can be used to downregulate inflammation processes. We have designed and synthesized new sulfated compounds based on small and biocompatible carbohydrates that are able to cross the BBB. A suitable protected donor and acceptor, obtained from a unique precursor, have been stereoselectively glycosylated to give an orthogonally protected cellobiose disaccharide. Selective deprotection and sulfation allowed the syntheses of four differentially sulfated disaccharides, which have been characterized by NMR, HRMS and MS/MS. Together with their partially protected precursors, the new compounds were tested on HEK-TLR4 cells. Our results show the potential of small oligosaccharides to modulate TLR4 activity, confirming the need for sulfation and the key role of the 6-sulfate groups to trigger TLR4 signalization.
Collapse
Affiliation(s)
- Rachid Naïtaleb
- Laboratoire de Glycochimie, des Antimicrobiens et des Agroressources, LG2A CNRS UMR 7378, Université de Picardie Jules Verne, 33 rue Saint Leu, 80039 Amiens, France.
| | | | | | | | | | | |
Collapse
|
8
|
Salles J, Briand-Mésange F, Trudel S, Ausseil J, Salles JP, Chap H. Can antidepressants unlock prescription of rimonabant in the fight against COVID-19? Mol Psychiatry 2021; 26:7091-7092. [PMID: 34282263 PMCID: PMC8287274 DOI: 10.1038/s41380-021-01221-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/22/2021] [Revised: 06/17/2021] [Accepted: 06/29/2021] [Indexed: 01/06/2023]
Affiliation(s)
- Juliette Salles
- grid.15781.3a0000 0001 0723 035XInfinity (Toulouse Institute for Infectious and Inflammatory Diseases), INSERM UMR1291, CNRS UMR5051, Université Toulouse III, Toulouse, France ,grid.411175.70000 0001 1457 2980CHU de Toulouse, Service de psychiatrie et psychologie, psychiatrie, Toulouse, France
| | - Fabienne Briand-Mésange
- grid.15781.3a0000 0001 0723 035XInfinity (Toulouse Institute for Infectious and Inflammatory Diseases), INSERM UMR1291, CNRS UMR5051, Université Toulouse III, Toulouse, France
| | - Stéphanie Trudel
- grid.15781.3a0000 0001 0723 035XInfinity (Toulouse Institute for Infectious and Inflammatory Diseases), INSERM UMR1291, CNRS UMR5051, Université Toulouse III, Toulouse, France ,grid.411175.70000 0001 1457 2980CHU Toulouse, Institut Fédératif de Biologie, Laboratoire de Biochimie, Toulouse, France
| | - Jérôme Ausseil
- grid.15781.3a0000 0001 0723 035XInfinity (Toulouse Institute for Infectious and Inflammatory Diseases), INSERM UMR1291, CNRS UMR5051, Université Toulouse III, Toulouse, France ,grid.411175.70000 0001 1457 2980CHU Toulouse, Institut Fédératif de Biologie, Laboratoire de Biochimie, Toulouse, France
| | - Jean-Pierre Salles
- grid.15781.3a0000 0001 0723 035XInfinity (Toulouse Institute for Infectious and Inflammatory Diseases), INSERM UMR1291, CNRS UMR5051, Université Toulouse III, Toulouse, France ,grid.411175.70000 0001 1457 2980CHU de Toulouse, Centre de référence du Syndrome de Prader–Willi et autres syndromes avec troubles du comportement alimentaire, Unité d’endocrinologie, obésités, maladies osseuses, génétique et gynécologie médicale, Toulouse, France
| | - Hugues Chap
- Infinity (Toulouse Institute for Infectious and Inflammatory Diseases), INSERM UMR1291, CNRS UMR5051, Université Toulouse III, Toulouse, France.
| |
Collapse
|
9
|
Yaker L, Kamel S, Ausseil J, Boullier A. Effects of Chronic Kidney Disease and Uremic Toxins on Extracellular Vesicle Biology. Toxins (Basel) 2020; 12:toxins12120811. [PMID: 33371311 PMCID: PMC7767379 DOI: 10.3390/toxins12120811] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2020] [Revised: 12/02/2020] [Accepted: 12/16/2020] [Indexed: 12/28/2022] Open
Abstract
Vascular calcification (VC) is a cardiovascular complication associated with a high mortality rate, especially in patients with diabetes, atherosclerosis or chronic kidney disease (CKD). In CKD patients, VC is associated with the accumulation of uremic toxins, such as indoxyl sulphate or inorganic phosphate, which can have a major impact in vascular remodeling. During VC, vascular smooth muscle cells (VSMCs) undergo an osteogenic switch and secrete extracellular vesicles (EVs) that are heterogeneous in terms of their origin and composition. Under physiological conditions, EVs are involved in cell-cell communication and the maintenance of cellular homeostasis. They contain high levels of calcification inhibitors, such as fetuin-A and matrix Gla protein. Under pathological conditions (and particularly in the presence of uremic toxins), the secreted EVs acquire a pro-calcifying profile and thereby act as nucleating foci for the crystallization of hydroxyapatite and the propagation of calcification. Here, we review the most recent findings on the EVs’ pathophysiological role in VC, the impact of uremic toxins on EV biogenesis and functions, the use of EVs as diagnostic biomarkers and the EVs’ therapeutic potential in CKD.
Collapse
Affiliation(s)
- Linda Yaker
- MP3CV-UR7517, CURS-Université de Picardie Jules Verne, Avenue de la Croix Jourdain, F-80054 Amiens, France; (L.Y.); (S.K.)
| | - Saïd Kamel
- MP3CV-UR7517, CURS-Université de Picardie Jules Verne, Avenue de la Croix Jourdain, F-80054 Amiens, France; (L.Y.); (S.K.)
- Laboratoire de Biochimie CHU Amiens-Picardie, Avenue de la Croix Jourdain, F-80054 Amiens, France
| | - Jérôme Ausseil
- INSERM UMR1043, CNRS UMR5282, University of Toulouse III, F-31024 Toulouse, France;
- CHU PURPAN—Institut Fédératif de Biologie, Laboratoire de Biochimie, Avenue de Grande Bretagne, F-31059 Toulouse, France
| | - Agnès Boullier
- MP3CV-UR7517, CURS-Université de Picardie Jules Verne, Avenue de la Croix Jourdain, F-80054 Amiens, France; (L.Y.); (S.K.)
- Laboratoire de Biochimie CHU Amiens-Picardie, Avenue de la Croix Jourdain, F-80054 Amiens, France
- Correspondence: ; Tel.: +33-322087019
| |
Collapse
|
10
|
Mansour A, Darwiche W, Yaker L, Da Nascimento S, Gomila C, Rossi C, Jung V, Sonnet P, Kamel S, Guerrera IC, Boullier A, Ausseil J. GFOGER Peptide Modifies the Protein Content of Extracellular Vesicles and Inhibits Vascular Calcification. Front Cell Dev Biol 2020; 8:589761. [PMID: 33330469 PMCID: PMC7734313 DOI: 10.3389/fcell.2020.589761] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2020] [Accepted: 10/26/2020] [Indexed: 12/22/2022] Open
Abstract
OBJECTIVE Vascular calcification (VC) is an active process during which vascular smooth muscle cells (VSMCs) undergo an osteogenic switch and release extracellular vesicles (EVs). In turn, the EVs serve as calcification foci via interaction with type 1 collagen (COL1). We recently showed that a specific, six-amino-acid repeat (GFOGER) in the sequence of COL1 was involved in the latter's interaction with integrins expressed on EVs. Our main objective was to test the GFOGER ability to inhibit VC. APPROACH We synthesized the GFOGER peptide and tested its ability to inhibit the inorganic phosphate (Pi)-induced calcification of VSMCs and aortic rings. Using mass spectrometry, we studied GFOGER's effect on the protein composition of EVs released from Pi-treated VSMCs. RESULTS Calcification of mouse VSMCs (MOVAS-1 cells), primary human VSMCs, and rat aortic rings was lower in the presence of GFOGER than with Pi alone (with relative decreases of 66, 58, and 91%, respectively; p < 0.001 for all) (no effect was observed with the scramble peptide GOERFG). A comparative proteomic analysis of EVs released from MOVAS-1 cells in the presence or absence of Pi highlighted significant differences in EVs' protein content. Interestingly, the expression of some of the EVs' proteins involved in the calcification process (such as osteogenic markers, TANK-binding kinase 1, and casein kinase II) was diminished in the presence of GFOGER peptide (data are available via ProteomeXchange with identifier PXD018169∗). The decrease of osteogenic marker expression observed in the presence of GFOGER was confirmed by q-RT-PCR analysis. CONCLUSION GFOGER peptide reduces vascular calcification by modifying the protein content of the subsequently released EVs, in particular by decreasing osteogenicswitching in VSMCs.
Collapse
Affiliation(s)
- Ali Mansour
- MP3CV-UR7517, CURS-Université de Picardie Jules Verne, Amiens, France
| | - Walaa Darwiche
- MP3CV-UR7517, CURS-Université de Picardie Jules Verne, Amiens, France
| | - Linda Yaker
- MP3CV-UR7517, CURS-Université de Picardie Jules Verne, Amiens, France
| | - Sophie Da Nascimento
- AGIR, UR4294, UFR de Pharmacie, Université de Picardie Jules Verne, Amiens, France
| | - Cathy Gomila
- MP3CV-UR7517, CURS-Université de Picardie Jules Verne, Amiens, France
| | - Claire Rossi
- Alliance Sorbonne Université, Université de Technologie de Compiègne, UMR7025 CNRS Enzyme and Cell Engineering Laboratory, Compiègne, France
| | - Vincent Jung
- Plateforme protéomique Necker, Faculté de Médecine Paris Descartes, Université de Paris – Structure Fédérative de Recherche Necker, INSERM US24/CNRS UMS3633, Paris, France
| | - Pascal Sonnet
- AGIR, UR4294, UFR de Pharmacie, Université de Picardie Jules Verne, Amiens, France
| | - Saïd Kamel
- MP3CV-UR7517, CURS-Université de Picardie Jules Verne, Amiens, France
- Laboratoire de Biochimie, Centre Hospitalier Universitaire d’ Amiens, Amiens, France
| | - Ida Chiara Guerrera
- Plateforme protéomique Necker, Faculté de Médecine Paris Descartes, Université de Paris – Structure Fédérative de Recherche Necker, INSERM US24/CNRS UMS3633, Paris, France
| | - Agnès Boullier
- MP3CV-UR7517, CURS-Université de Picardie Jules Verne, Amiens, France
- Laboratoire de Biochimie, Centre Hospitalier Universitaire d’ Amiens, Amiens, France
| | - Jérôme Ausseil
- MP3CV-UR7517, CURS-Université de Picardie Jules Verne, Amiens, France
- Centre de Physiopathologie Toulouse Purpan, INSERM UMR1043 – CNRS UMR5282 – Université Toulouse III, Toulouse, France
- CHU Toulouse – Institut Fédératif de Biologie, Laboratoire de Biochimie, Toulouse, France
| |
Collapse
|
11
|
Briand-Mésange F, Pons V, Allart S, Masquelier J, Chicanne G, Beton N, Payrastre B, Muccioli GG, Ausseil J, Davignon JL, Salles JP, Chap H. Glycerophosphodiesterase 3 (GDE3) is a lysophosphatidylinositol-specific ectophospholipase C acting as an endocannabinoid signaling switch. J Biol Chem 2020; 295:15767-15781. [PMID: 32917725 DOI: 10.1074/jbc.ra120.015278] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2020] [Revised: 09/03/2020] [Indexed: 12/11/2022] Open
Abstract
Endocannabinoid signaling plays a regulatory role in various (neuro)biological functions. 2-arachidonoylglycerol (2-AG) is the most abundant endocannabinoid, and although its canonical biosynthetic pathway involving phosphoinositide-specific phospholipase C and diacylglycerol lipase α is known, alternative pathways remain unsettled. Here, we characterize a noncanonical pathway implicating glycerophosphodiesterase 3 (GDE3, from GDPD2 gene). Human GDE3 expressed in HEK293T cell membranes catalyzed the conversion of lysophosphatidylinositol (LPI) into monoacylglycerol and inositol-1-phosphate. The enzyme was equally active against 1-acyl and 2-acyl LPI. When using 2-acyl LPI, where arachidonic acid is the predominant fatty acid, LC-MS analysis identified 2-AG as the main product of LPI hydrolysis by GDE3. Furthermore, inositol-1-phosphate release into the medium occurred upon addition of LPI to intact cells, suggesting that GDE3 is actually an ecto-lysophospholipase C. In cells expressing G-protein-coupled receptor GPR55, GDE3 abolished 1-acyl LPI-induced signaling. In contrast, upon simultaneous ex-pression of GDE3 and cannabinoid receptor CB2, 2-acyl LPI evoked the same signal as that induced by 2-AG. These data strongly suggest that, in addition to degrading the GPR55 LPI ligand, GDE3 can act as a switch between GPR55 and CB2 signaling. Coincident with a major expression of both GDE3 and CB2 in the spleen, spleens from transgenic mice lacking GDE3 displayed doubling of LPI content compared with WT mice. Decreased production of 2-AG in whole spleen was also observed, supporting the in vivo relevance of our findings. These data thus open a new research avenue in the field of endocannabinoid generation and reinforce the view of GPR55 and LPI being genuine actors of the endocannabinoid system.
Collapse
Affiliation(s)
- Fabienne Briand-Mésange
- Center for Physiopathology of Toulouse Purpan, University of Toulouse, Toulouse, France; National Center for Scientific Research, Toulouse, France; National Institute of Health and Medical Research, Paul Sabatier University, Toulouse, France
| | - Véronique Pons
- Institute of Metabolic and Cardiovascular Diseases, Toulouse, France; National Institute of Health and Medical Research, Paul Sabatier University, Toulouse, France
| | - Sophie Allart
- Center for Physiopathology of Toulouse Purpan, University of Toulouse, Toulouse, France; National Center for Scientific Research, Toulouse, France; National Institute of Health and Medical Research, Paul Sabatier University, Toulouse, France
| | - Julien Masquelier
- Bioanalysis and Pharmacology of Bioactive Lipids Research Group, Louvain Drug Research Institute, Catholic University of Louvain, Brussels, Belgium
| | - Gaëtan Chicanne
- Institute of Metabolic and Cardiovascular Diseases, Toulouse, France; National Institute of Health and Medical Research, Paul Sabatier University, Toulouse, France
| | - Nicolas Beton
- Center for Physiopathology of Toulouse Purpan, University of Toulouse, Toulouse, France; National Center for Scientific Research, Toulouse, France; National Institute of Health and Medical Research, Paul Sabatier University, Toulouse, France
| | - Bernard Payrastre
- Institute of Metabolic and Cardiovascular Diseases, Toulouse, France; National Institute of Health and Medical Research, Paul Sabatier University, Toulouse, France
| | - Giulio G Muccioli
- Bioanalysis and Pharmacology of Bioactive Lipids Research Group, Louvain Drug Research Institute, Catholic University of Louvain, Brussels, Belgium
| | - Jérôme Ausseil
- Center for Physiopathology of Toulouse Purpan, University of Toulouse, Toulouse, France; National Center for Scientific Research, Toulouse, France; National Institute of Health and Medical Research, Paul Sabatier University, Toulouse, France
| | - Jean-Luc Davignon
- Center for Physiopathology of Toulouse Purpan, University of Toulouse, Toulouse, France; National Center for Scientific Research, Toulouse, France; National Institute of Health and Medical Research, Paul Sabatier University, Toulouse, France
| | - Jean-Pierre Salles
- Center for Physiopathology of Toulouse Purpan, University of Toulouse, Toulouse, France; National Center for Scientific Research, Toulouse, France; National Institute of Health and Medical Research, Paul Sabatier University, Toulouse, France
| | - Hugues Chap
- Center for Physiopathology of Toulouse Purpan, University of Toulouse, Toulouse, France; National Center for Scientific Research, Toulouse, France; National Institute of Health and Medical Research, Paul Sabatier University, Toulouse, France.
| |
Collapse
|
12
|
Briand‐Mésange F, Trudel S, Salles J, Ausseil J, Salles J, Chap H. Possible Role of Adipose Tissue and the Endocannabinoid System in Coronavirus Disease 2019 Pathogenesis: Can Rimonabant Return? Obesity (Silver Spring) 2020; 28:1580-1581. [PMID: 32463562 PMCID: PMC7283662 DOI: 10.1002/oby.22916] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/03/2020] [Revised: 05/21/2020] [Accepted: 05/26/2020] [Indexed: 12/17/2022]
Affiliation(s)
- Fabienne Briand‐Mésange
- Centre de Physiopathologie de Toulouse PurpanU5282Centre National de la Recherche ScientifiqueU1043Institut National de la Santé et de la Recherche MédicaleUniversité de Toulouse–Université Paul SabatierToulouseFrance
| | - Stéphanie Trudel
- Centre de Physiopathologie de Toulouse PurpanU5282Centre National de la Recherche ScientifiqueU1043Institut National de la Santé et de la Recherche MédicaleUniversité de Toulouse–Université Paul SabatierToulouseFrance
| | - Juliette Salles
- Centre de Physiopathologie de Toulouse PurpanU5282Centre National de la Recherche ScientifiqueU1043Institut National de la Santé et de la Recherche MédicaleUniversité de Toulouse–Université Paul SabatierToulouseFrance
| | - Jérôme Ausseil
- Centre de Physiopathologie de Toulouse PurpanU5282Centre National de la Recherche ScientifiqueU1043Institut National de la Santé et de la Recherche MédicaleUniversité de Toulouse–Université Paul SabatierToulouseFrance
| | - Jean‐Pierre Salles
- Centre de Physiopathologie de Toulouse PurpanU5282Centre National de la Recherche ScientifiqueU1043Institut National de la Santé et de la Recherche MédicaleUniversité de Toulouse–Université Paul SabatierToulouseFrance
| | - Hugues Chap
- Centre de Physiopathologie de Toulouse PurpanU5282Centre National de la Recherche ScientifiqueU1043Institut National de la Santé et de la Recherche MédicaleUniversité de Toulouse–Université Paul SabatierToulouseFrance
| |
Collapse
|
13
|
Hocquemiller M, Hemsley KM, Douglass ML, Tamang SJ, Neumann D, King BM, Beard H, Trim PJ, Winner LK, Lau AA, Snel MF, Gomila C, Ausseil J, Mei X, Giersch L, Plavsic M, Laufer R. AAVrh10 Vector Corrects Disease Pathology in MPS IIIA Mice and Achieves Widespread Distribution of SGSH in Large Animal Brains. Mol Ther Methods Clin Dev 2019; 17:174-187. [PMID: 31909089 PMCID: PMC6940615 DOI: 10.1016/j.omtm.2019.12.001] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/13/2019] [Accepted: 12/02/2019] [Indexed: 12/23/2022]
Abstract
Patients with mucopolysaccharidosis type IIIA (MPS IIIA) lack the lysosomal enzyme sulfamidase (SGSH), which is responsible for the degradation of heparan sulfate (HS). Build-up of undegraded HS results in severe progressive neurodegeneration for which there is currently no treatment. The ability of the vector adeno-associated virus (AAV)rh.10-CAG-SGSH (LYS-SAF302) to correct disease pathology was evaluated in a mouse model for MPS IIIA. LYS-SAF302 was administered to 5-week-old MPS IIIA mice at three different doses (8.6E+08, 4.1E+10, and 9.0E+10 vector genomes [vg]/animal) injected into the caudate putamen/striatum and thalamus. LYS-SAF302 was able to dose-dependently correct or significantly reduce HS storage, secondary accumulation of GM2 and GM3 gangliosides, ubiquitin-reactive axonal spheroid lesions, lysosomal expansion, and neuroinflammation at 12 weeks and 25 weeks post-dosing. To study SGSH distribution in the brain of large animals, LYS-SAF302 was injected into the subcortical white matter of dogs (1.0E+12 or 2.0E+12 vg/animal) and cynomolgus monkeys (7.2E+11 vg/animal). Increases of SGSH enzyme activity of at least 20% above endogenous levels were detected in 78% (dogs 4 weeks after injection) and 97% (monkeys 6 weeks after injection) of the total brain volume. Taken together, these data validate intraparenchymal AAV administration as a promising method to achieve widespread enzyme distribution and correction of disease pathology in MPS IIIA.
Collapse
Affiliation(s)
| | - Kim M Hemsley
- Childhood Dementia Research Group, Hopwood Centre for Neurobiology, Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia
| | - Meghan L Douglass
- Childhood Dementia Research Group, Hopwood Centre for Neurobiology, Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia
| | - Sarah J Tamang
- Childhood Dementia Research Group, Hopwood Centre for Neurobiology, Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia
| | - Daniel Neumann
- Childhood Dementia Research Group, Hopwood Centre for Neurobiology, Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia
| | - Barbara M King
- Childhood Dementia Research Group, Hopwood Centre for Neurobiology, Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia
| | - Helen Beard
- Childhood Dementia Research Group, Hopwood Centre for Neurobiology, Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia
| | - Paul J Trim
- Mass Spectrometry Core Facility, SAHMRI, Adelaide, SA 5000, Australia
| | - Leanne K Winner
- Childhood Dementia Research Group, Hopwood Centre for Neurobiology, Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia
| | - Adeline A Lau
- Childhood Dementia Research Group, Hopwood Centre for Neurobiology, Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, SA 5000, Australia
| | - Marten F Snel
- Mass Spectrometry Core Facility, SAHMRI, Adelaide, SA 5000, Australia
| | - Cathy Gomila
- Laboratoire de Biochimie Métabolique, CHU Amiens Picardie, 80054 Amiens, France
| | - Jérôme Ausseil
- Unité INSERM U1043, Centre de Physiopathologie Toulouse Purpan (CPTP), Université Paul Sabatier, 31024 Toulouse, France
| | - Xin Mei
- Lysogene, 18-20 rue Jacques Dulud, 92200 Neuilly-sur-Seine, France
| | - Laura Giersch
- Lysogene, 18-20 rue Jacques Dulud, 92200 Neuilly-sur-Seine, France
| | - Mark Plavsic
- Lysogene, 18-20 rue Jacques Dulud, 92200 Neuilly-sur-Seine, France
| | - Ralph Laufer
- Lysogene, 18-20 rue Jacques Dulud, 92200 Neuilly-sur-Seine, France
| |
Collapse
|
14
|
Tebani A, Abily-Donval L, Schmitz-Afonso I, Piraud M, Ausseil J, Zerimech F, Pilon C, Pereira T, Marret S, Afonso C, Bekri S. Analysis of Mucopolysaccharidosis Type VI through Integrative Functional Metabolomics. Int J Mol Sci 2019; 20:ijms20020446. [PMID: 30669586 PMCID: PMC6359186 DOI: 10.3390/ijms20020446] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2018] [Revised: 01/17/2019] [Accepted: 01/18/2019] [Indexed: 12/12/2022] Open
Abstract
Metabolic phenotyping is poised as a powerful and promising tool for biomarker discovery in inherited metabolic diseases. However, few studies applied this approach to mcopolysaccharidoses (MPS). Thus, this innovative functional approach may unveil comprehensive impairments in MPS biology. This study explores mcopolysaccharidosis VI (MPS VI) or Maroteaux–Lamy syndrome (OMIM #253200) which is an autosomal recessive lysosomal storage disease caused by the deficiency of arylsulfatase B enzyme. Urine samples were collected from 16 MPS VI patients and 66 healthy control individuals. Untargeted metabolomics analysis was applied using ultra-high-performance liquid chromatography combined with ion mobility and high-resolution mass spectrometry. Furthermore, dermatan sulfate, amino acids, carnitine, and acylcarnitine profiles were quantified using liquid chromatography coupled to tandem mass spectrometry. Univariate analysis and multivariate data modeling were used for integrative analysis and discriminant metabolites selection. Pathway analysis was done to unveil impaired metabolism. The study revealed significant differential biochemical patterns using multivariate data modeling. Pathway analysis revealed that several major amino acid pathways were dysregulated in MPS VI. Integrative analysis of targeted and untargeted metabolomics data with in silico results yielded arginine-proline, histidine, and glutathione metabolism being the most affected. This study is one of the first metabolic phenotyping studies of MPS VI. The findings might shed light on molecular understanding of MPS pathophysiology to develop further MPS studies to enhance diagnosis and treatments of this rare condition.
Collapse
Affiliation(s)
- Abdellah Tebani
- Department of Metabolic Biochemistry, Rouen University Hospital, 76000 Rouen, France.
- Normandie University, UNIROUEN, CHU Rouen, INSERM U1245, 76000 Rouen, France.
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA, 76000 Rouen, France.
| | - Lenaig Abily-Donval
- Normandie University, UNIROUEN, CHU Rouen, INSERM U1245, 76000 Rouen, France.
- Department of Neonatal Pediatrics, Intensive Care and Neuropediatrics, Rouen University Hospital, 76031 Rouen, France.
| | | | - Monique Piraud
- Service de Biochimie et Biologie Moléculaire Grand Est, Unité des Maladies Héréditaires du Métabolisme et Dépistage Néonatal, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, 69002 Lyon, France.
| | - Jérôme Ausseil
- INSERM U1088, Laboratoire de Biochimie Métabolique, Centre de Biologie Humaine, CHU Sud, 80054 Amiens CEDEX, France.
| | - Farid Zerimech
- Laboratoire de Biochimie et Biologie Moléculaire, Université de Lille et Pôle de Biologie Pathologie Génétique du CHRU de Lille, 59000 Lille, France.
| | - Carine Pilon
- Department of Metabolic Biochemistry, Rouen University Hospital, 76000 Rouen, France.
| | - Tony Pereira
- Department of Pharmacology, Rouen University Hospital, 76000 Rouen, France.
| | - Stéphane Marret
- Normandie University, UNIROUEN, CHU Rouen, INSERM U1245, 76000 Rouen, France.
- Department of Neonatal Pediatrics, Intensive Care and Neuropediatrics, Rouen University Hospital, 76031 Rouen, France.
| | - Carlos Afonso
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA, 76000 Rouen, France.
| | - Soumeya Bekri
- Department of Metabolic Biochemistry, Rouen University Hospital, 76000 Rouen, France.
- Normandie University, UNIROUEN, CHU Rouen, INSERM U1245, 76000 Rouen, France.
| |
Collapse
|
15
|
Leke A, Raucy M, Chazal C, Goudjil S, Caron-Lesenechal E, Tourneux P, Ausseil J. Évaluation de la masse fonctionnelle intestinale chez des nouveau-nés porteurs de dérivation intestinale par le dosage de la Citrulline plasmatique. NUTR CLIN METAB 2018. [DOI: 10.1016/j.nupar.2018.09.184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
16
|
Tebani A, Abily-Donval L, Schmitz-Afonso I, Héron B, Piraud M, Ausseil J, Zerimech F, Gonzalez B, Marret S, Afonso C, Bekri S. Unveiling metabolic remodeling in mucopolysaccharidosis type III through integrative metabolomics and pathway analysis. J Transl Med 2018; 16:248. [PMID: 30180851 PMCID: PMC6122730 DOI: 10.1186/s12967-018-1625-1] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2018] [Accepted: 08/30/2018] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Metabolomics represent a valuable tool to recover biological information using body fluids and may help to characterize pathophysiological mechanisms of the studied disease. This approach has not been widely used to explore inherited metabolic diseases. This study investigates mucopolysaccharidosis type III (MPS III). A thorough and holistic understanding of metabolic remodeling in MPS III may allow the development, improvement and personalization of patient care. METHODS We applied both targeted and untargeted metabolomics to urine samples obtained from a French cohort of 49 patients, consisting of 13 MPS IIIA, 16 MPS IIIB, 13 MPS IIIC, and 7 MPS IIID, along with 66 controls. The analytical strategy is based on ultra-high-performance liquid chromatography combined with ion mobility and high-resolution mass spectrometry. Twenty-four amino acids have been assessed using tandem mass spectrometry combined with liquid chromatography. Multivariate data modeling has been used for discriminant metabolite selection. Pathway analysis has been performed to retrieve metabolic pathways impairments. RESULTS Data analysis revealed distinct biochemical profiles. These metabolic patterns, particularly those related to the amino acid metabolisms, allowed the different studied groups to be distinguished. Pathway analysis unveiled major amino acid pathways impairments in MPS III mainly arginine-proline metabolism and urea cycle metabolism. CONCLUSION This represents one of the first metabolomics-based investigations of MPS III. These results may shed light on MPS III pathophysiology and could help to set more targeted studies to infer the biomarkers of the affected pathways, which is crucial for rare conditions such as MPS III.
Collapse
Affiliation(s)
- Abdellah Tebani
- Department of Metabolic Biochemistry, Rouen University Hospital, 76000, Rouen Cedex, France.,Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000, Rouen, France.,Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA, 76000, Rouen, France
| | - Lenaig Abily-Donval
- Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000, Rouen, France.,Department of Neonatal Pediatrics, Intensive Care and Neuropediatrics, Rouen University Hospital, 76031, Rouen, France
| | | | - Bénédicte Héron
- Department of Pediatric Neurology, Reference Center of Lysosomal Diseases, Trousseau Hospital, APHP and Sorbonne Université, GRC No 19, Pathologies Congénitales du Cervelet-LeucoDystrophies, AP-HP, Hôpital Armand Trousseau, 75012, Paris, France
| | - Monique Piraud
- Service de Biochimie et Biologie Moléculaire Grand Est, Unité des Maladies Héréditaires du Métabolisme et Dépistage Néonatal, Centre de Biologie et de Pathologie Est, CHU de Lyon, Lyon, France
| | - Jérôme Ausseil
- INSERM U1088, Laboratoire de Biochimie Métabolique, Centre de Biologie Humaine, CHU Sud, 80054, Amiens Cedex, France
| | - Farid Zerimech
- Laboratoire de Biochimie et Biologie Moléculaire, Université de Lille et Pôle de Biologie Pathologie Génétique du CHRU de Lille, 59000, Lille, France
| | - Bruno Gonzalez
- Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000, Rouen, France
| | - Stéphane Marret
- Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000, Rouen, France.,Department of Neonatal Pediatrics, Intensive Care and Neuropediatrics, Rouen University Hospital, 76031, Rouen, France
| | - Carlos Afonso
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA, 76000, Rouen, France
| | - Soumeya Bekri
- Department of Metabolic Biochemistry, Rouen University Hospital, 76000, Rouen Cedex, France. .,Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000, Rouen, France.
| |
Collapse
|
17
|
Puy V, Darwiche W, Trudel S, Gomila C, Lony C, Puy L, Lefebvre T, Vitry S, Boullier A, Karim Z, Ausseil J. Predominant role of microglia in brain iron retention in Sanfilippo syndrome, a pediatric neurodegenerative disease. Glia 2018; 66:1709-1723. [DOI: 10.1002/glia.23335] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2017] [Revised: 03/03/2018] [Accepted: 03/16/2018] [Indexed: 02/06/2023]
Affiliation(s)
- Vincent Puy
- Unité INSERM U1088, CURS-Université de Picardie Jules Verne; Amiens F-80054 France
- Laboratoire de Biochimie Métabolique, CHU Amiens Picardie; Amiens F-80054 France
| | - Walaa Darwiche
- Unité INSERM U1088, CURS-Université de Picardie Jules Verne; Amiens F-80054 France
| | - Stéphanie Trudel
- Laboratoire d'Oncobiologie Moléculaire, CHU Amiens Picardie, F-80054 Amiens, France and EA4666 Lymphocyte Normal, Pathologique et Cancers (LNPC); CURS-Université de Picardie Jules Verne; Amiens F-80054 France
| | - Cathy Gomila
- Unité INSERM U1088, CURS-Université de Picardie Jules Verne; Amiens F-80054 France
- Laboratoire de Biochimie Métabolique, CHU Amiens Picardie; Amiens F-80054 France
| | - Christelle Lony
- Unité INSERM U1088, CURS-Université de Picardie Jules Verne; Amiens F-80054 France
| | - Laurent Puy
- Département de Neurologie et Laboratoire de Neuroscience Fonctionnelle EA-4559; CHU Amiens Picardie; Amiens F-80054, France
| | - Thibaud Lefebvre
- INSERM U1149, Université Paris Diderot, site Bichat, Sorbonne Paris Cité, F-75018 Paris, France, DHU UNITY, Laboratory of Excellence, GR-Ex; Paris France
| | - Sandrine Vitry
- Unité de NeuroImmunologie Virale, Institut Pasteur; Paris F-75015 France
| | - Agnès Boullier
- Unité INSERM U1088, CURS-Université de Picardie Jules Verne; Amiens F-80054 France
- Laboratoire de Biochimie Métabolique, CHU Amiens Picardie; Amiens F-80054 France
| | - Zoubida Karim
- INSERM U1149, Université Paris Diderot, site Bichat, Sorbonne Paris Cité, F-75018 Paris, France, DHU UNITY, Laboratory of Excellence, GR-Ex; Paris France
| | - Jérôme Ausseil
- Unité INSERM U1088, CURS-Université de Picardie Jules Verne; Amiens F-80054 France
- Laboratoire de Biochimie Métabolique, CHU Amiens Picardie; Amiens F-80054 France
| |
Collapse
|
18
|
Rouillon J, Lefebvre T, Denard J, Puy V, Daher R, Ausseil J, Zocevic A, Fogel P, Peoc'h K, Wong B, Servais L, Voit T, Puy H, Karim Z, Svinartchouk F. High urinary ferritin reflects myoglobin iron evacuation in DMD patients. Neuromuscul Disord 2018; 28:564-571. [PMID: 29776718 DOI: 10.1016/j.nmd.2018.03.008] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2017] [Revised: 12/26/2017] [Accepted: 03/14/2018] [Indexed: 12/15/2022]
Abstract
Duchenne muscular dystrophy (DMD) is an X-linked disease caused by mutations in the dystrophin gene leading to the absence of the normal dystrophin protein. The efforts of many laboratories brought new treatments of DMD to the reality, but ongoing and forthcoming clinical trials suffer from absence of valuable biomarkers permitting to follow the outcome of the treatment day by day and to adjust the treatment if needed. In the present study the levels of 128 urinary proteins including growth factors, cytokines and chemokines were compared in urine of DMD patients and age related control subjects by antibody array approach. Surprisingly, statistically significant difference was observed only for urinary ferritin whose level was 50 times higher in young DMD patients. To explain the observed high urinary ferritin content we analysed the levels of iron, iron containing proteins and proteins involved in regulation of iron metabolism in serum and urine of DMD patients and their age-matched healthy controls. Obtained data strongly suggest that elevated level of urinary ferritin is functionally linked to the renal management of myoglobin iron derived from leaky muscles of DMD patients. This first observation of the high level of ferritin in urine of DMD patients permits to consider this protein as a new urinary biomarker in muscular dystrophies and sheds light on the mechanisms of iron metabolism and kidney functioning in DMD.
Collapse
Affiliation(s)
| | - Thibaud Lefebvre
- INSERM U1149 CNRS ERL 8252, Centre de Recherche sur l'inflammation, Université Paris Diderot, site Bichat, Sorbonne Paris Cité, France, 16 rue Henri Huchard, 75018 Paris, France; Laboratory of excellence, GR-Ex, Paris, France
| | | | - Vincent Puy
- Unité INSERM U1088, CURS-Université de Picardie Jules Verne, Amiens, France; Laboratoire de Biochimie, CHU Amiens, F-80054 Amiens, France
| | - Raed Daher
- INSERM U1149 CNRS ERL 8252, Centre de Recherche sur l'inflammation, Université Paris Diderot, site Bichat, Sorbonne Paris Cité, France, 16 rue Henri Huchard, 75018 Paris, France; Laboratory of excellence, GR-Ex, Paris, France
| | - Jérôme Ausseil
- Unité INSERM U1088, CURS-Université de Picardie Jules Verne, Amiens, France; Laboratoire de Biochimie, CHU Amiens, F-80054 Amiens, France
| | | | | | - Katell Peoc'h
- INSERM U1149 CNRS ERL 8252, Centre de Recherche sur l'inflammation, Université Paris Diderot, site Bichat, Sorbonne Paris Cité, France, 16 rue Henri Huchard, 75018 Paris, France
| | - Brenda Wong
- Division of Pediatric Neurology, Cincinnati Children's Hospital Medical Center, USA
| | - Laurent Servais
- Service of Clinical Trials and Databases, Institut de Myologie, Paris, France
| | - Thomas Voit
- University College London, NIHR Biomedical Research Centre, Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK
| | - Herve Puy
- INSERM U1149 CNRS ERL 8252, Centre de Recherche sur l'inflammation, Université Paris Diderot, site Bichat, Sorbonne Paris Cité, France, 16 rue Henri Huchard, 75018 Paris, France; Laboratory of excellence, GR-Ex, Paris, France
| | - Zoubida Karim
- INSERM U1149 CNRS ERL 8252, Centre de Recherche sur l'inflammation, Université Paris Diderot, site Bichat, Sorbonne Paris Cité, France, 16 rue Henri Huchard, 75018 Paris, France; Laboratory of excellence, GR-Ex, Paris, France
| | | |
Collapse
|
19
|
Daher I, Le Dieu-Lugon B, Dourmap N, Lecuyer M, Ramet L, Gomila C, Ausseil J, Marret S, Leroux P, Roy V, El Mestikawy S, Daumas S, Gonzalez B, Leroux-Nicollet I, Cleren C. Magnesium Sulfate Prevents Neurochemical and Long-Term Behavioral Consequences of Neonatal Excitotoxic Lesions: Comparison Between Male and Female Mice. J Neuropathol Exp Neurol 2017; 76:883-897. [PMID: 28922852 DOI: 10.1093/jnen/nlx073] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Magnesium sulfate (MgSO4) administration to mothers at risk of preterm delivery is proposed as a neuroprotective strategy against neurological alterations such as cerebral palsy in newborns. However, long-term beneficial or adverse effects of MgSO4 and sex-specific sensitivity remain to be investigated. We conducted behavioral and neurochemical studies of MgSO4 effects in males and females, from the perinatal period to adolescence in a mouse model of cerebral neonatal lesion. The lesion was produced in 5-day-old (P5) pups by ibotenate intracortical injection. MgSO4 (600 mg/kg, i.p.) prior to ibotenate prevented lesion-induced sensorimotor alterations in both sexes at P6 and P7. The lesion increased glutamate level at P10 in the prefrontal cortex, which was prevented by MgSO4 in males. In neonatally lesioned adolescent mice, males exhibited more sequelae than females in motor and cognitive functions. In the perirhinal cortex of adolescent mice, the neonatal lesion induced an increase in vesicular glutamate transporter 1 density in males only, which was negatively correlated with cognitive scores. Long-term sequelae were prevented by neonatal MgSO4 administration. MgSO4 never induced short- or long-term deleterious effect on its own. These results also strongly suggest that sex-specific neuroprotection should be foreseen in preterm infants.
Collapse
Affiliation(s)
- Ismaël Daher
- Department of Neonatal Pediatrics and Intensive Care - Neuropediatrics, Normandie Univ, UNIROUEN, INSERM U1245, and Rouen University Hospital, Rouen, France; Normal and Pathological Glutamatergic Systems, Neuroscience Paris Seine, IBPS, INSERM U1130, CNRS UMR 8246 Université Pierre et Marie Curie, Paris, France; INSERM U1088, Laboratoire de Biochimie, Centre de Biologie Humaine, Amiens-Picardie University Hospital, Amiens, France; Normandie Univ, UNIROUEN, PSY-NCA, Rouen, France
| | - Bérénice Le Dieu-Lugon
- Department of Neonatal Pediatrics and Intensive Care - Neuropediatrics, Normandie Univ, UNIROUEN, INSERM U1245, and Rouen University Hospital, Rouen, France; Normal and Pathological Glutamatergic Systems, Neuroscience Paris Seine, IBPS, INSERM U1130, CNRS UMR 8246 Université Pierre et Marie Curie, Paris, France; INSERM U1088, Laboratoire de Biochimie, Centre de Biologie Humaine, Amiens-Picardie University Hospital, Amiens, France; Normandie Univ, UNIROUEN, PSY-NCA, Rouen, France
| | - Nathalie Dourmap
- Department of Neonatal Pediatrics and Intensive Care - Neuropediatrics, Normandie Univ, UNIROUEN, INSERM U1245, and Rouen University Hospital, Rouen, France; Normal and Pathological Glutamatergic Systems, Neuroscience Paris Seine, IBPS, INSERM U1130, CNRS UMR 8246 Université Pierre et Marie Curie, Paris, France; INSERM U1088, Laboratoire de Biochimie, Centre de Biologie Humaine, Amiens-Picardie University Hospital, Amiens, France; Normandie Univ, UNIROUEN, PSY-NCA, Rouen, France
| | - Matthieu Lecuyer
- Department of Neonatal Pediatrics and Intensive Care - Neuropediatrics, Normandie Univ, UNIROUEN, INSERM U1245, and Rouen University Hospital, Rouen, France; Normal and Pathological Glutamatergic Systems, Neuroscience Paris Seine, IBPS, INSERM U1130, CNRS UMR 8246 Université Pierre et Marie Curie, Paris, France; INSERM U1088, Laboratoire de Biochimie, Centre de Biologie Humaine, Amiens-Picardie University Hospital, Amiens, France; Normandie Univ, UNIROUEN, PSY-NCA, Rouen, France
| | - Lauriane Ramet
- Department of Neonatal Pediatrics and Intensive Care - Neuropediatrics, Normandie Univ, UNIROUEN, INSERM U1245, and Rouen University Hospital, Rouen, France; Normal and Pathological Glutamatergic Systems, Neuroscience Paris Seine, IBPS, INSERM U1130, CNRS UMR 8246 Université Pierre et Marie Curie, Paris, France; INSERM U1088, Laboratoire de Biochimie, Centre de Biologie Humaine, Amiens-Picardie University Hospital, Amiens, France; Normandie Univ, UNIROUEN, PSY-NCA, Rouen, France
| | - Cathy Gomila
- Department of Neonatal Pediatrics and Intensive Care - Neuropediatrics, Normandie Univ, UNIROUEN, INSERM U1245, and Rouen University Hospital, Rouen, France; Normal and Pathological Glutamatergic Systems, Neuroscience Paris Seine, IBPS, INSERM U1130, CNRS UMR 8246 Université Pierre et Marie Curie, Paris, France; INSERM U1088, Laboratoire de Biochimie, Centre de Biologie Humaine, Amiens-Picardie University Hospital, Amiens, France; Normandie Univ, UNIROUEN, PSY-NCA, Rouen, France
| | - Jérôme Ausseil
- Department of Neonatal Pediatrics and Intensive Care - Neuropediatrics, Normandie Univ, UNIROUEN, INSERM U1245, and Rouen University Hospital, Rouen, France; Normal and Pathological Glutamatergic Systems, Neuroscience Paris Seine, IBPS, INSERM U1130, CNRS UMR 8246 Université Pierre et Marie Curie, Paris, France; INSERM U1088, Laboratoire de Biochimie, Centre de Biologie Humaine, Amiens-Picardie University Hospital, Amiens, France; Normandie Univ, UNIROUEN, PSY-NCA, Rouen, France
| | - Stéphane Marret
- Department of Neonatal Pediatrics and Intensive Care - Neuropediatrics, Normandie Univ, UNIROUEN, INSERM U1245, and Rouen University Hospital, Rouen, France; Normal and Pathological Glutamatergic Systems, Neuroscience Paris Seine, IBPS, INSERM U1130, CNRS UMR 8246 Université Pierre et Marie Curie, Paris, France; INSERM U1088, Laboratoire de Biochimie, Centre de Biologie Humaine, Amiens-Picardie University Hospital, Amiens, France; Normandie Univ, UNIROUEN, PSY-NCA, Rouen, France
| | - Philippe Leroux
- Department of Neonatal Pediatrics and Intensive Care - Neuropediatrics, Normandie Univ, UNIROUEN, INSERM U1245, and Rouen University Hospital, Rouen, France; Normal and Pathological Glutamatergic Systems, Neuroscience Paris Seine, IBPS, INSERM U1130, CNRS UMR 8246 Université Pierre et Marie Curie, Paris, France; INSERM U1088, Laboratoire de Biochimie, Centre de Biologie Humaine, Amiens-Picardie University Hospital, Amiens, France; Normandie Univ, UNIROUEN, PSY-NCA, Rouen, France
| | - Vincent Roy
- Department of Neonatal Pediatrics and Intensive Care - Neuropediatrics, Normandie Univ, UNIROUEN, INSERM U1245, and Rouen University Hospital, Rouen, France; Normal and Pathological Glutamatergic Systems, Neuroscience Paris Seine, IBPS, INSERM U1130, CNRS UMR 8246 Université Pierre et Marie Curie, Paris, France; INSERM U1088, Laboratoire de Biochimie, Centre de Biologie Humaine, Amiens-Picardie University Hospital, Amiens, France; Normandie Univ, UNIROUEN, PSY-NCA, Rouen, France
| | - Salah El Mestikawy
- Department of Neonatal Pediatrics and Intensive Care - Neuropediatrics, Normandie Univ, UNIROUEN, INSERM U1245, and Rouen University Hospital, Rouen, France; Normal and Pathological Glutamatergic Systems, Neuroscience Paris Seine, IBPS, INSERM U1130, CNRS UMR 8246 Université Pierre et Marie Curie, Paris, France; INSERM U1088, Laboratoire de Biochimie, Centre de Biologie Humaine, Amiens-Picardie University Hospital, Amiens, France; Normandie Univ, UNIROUEN, PSY-NCA, Rouen, France
| | - Stéphanie Daumas
- Department of Neonatal Pediatrics and Intensive Care - Neuropediatrics, Normandie Univ, UNIROUEN, INSERM U1245, and Rouen University Hospital, Rouen, France; Normal and Pathological Glutamatergic Systems, Neuroscience Paris Seine, IBPS, INSERM U1130, CNRS UMR 8246 Université Pierre et Marie Curie, Paris, France; INSERM U1088, Laboratoire de Biochimie, Centre de Biologie Humaine, Amiens-Picardie University Hospital, Amiens, France; Normandie Univ, UNIROUEN, PSY-NCA, Rouen, France
| | - Bruno Gonzalez
- Department of Neonatal Pediatrics and Intensive Care - Neuropediatrics, Normandie Univ, UNIROUEN, INSERM U1245, and Rouen University Hospital, Rouen, France; Normal and Pathological Glutamatergic Systems, Neuroscience Paris Seine, IBPS, INSERM U1130, CNRS UMR 8246 Université Pierre et Marie Curie, Paris, France; INSERM U1088, Laboratoire de Biochimie, Centre de Biologie Humaine, Amiens-Picardie University Hospital, Amiens, France; Normandie Univ, UNIROUEN, PSY-NCA, Rouen, France
| | - Isabelle Leroux-Nicollet
- Department of Neonatal Pediatrics and Intensive Care - Neuropediatrics, Normandie Univ, UNIROUEN, INSERM U1245, and Rouen University Hospital, Rouen, France; Normal and Pathological Glutamatergic Systems, Neuroscience Paris Seine, IBPS, INSERM U1130, CNRS UMR 8246 Université Pierre et Marie Curie, Paris, France; INSERM U1088, Laboratoire de Biochimie, Centre de Biologie Humaine, Amiens-Picardie University Hospital, Amiens, France; Normandie Univ, UNIROUEN, PSY-NCA, Rouen, France
| | - Carine Cleren
- Department of Neonatal Pediatrics and Intensive Care - Neuropediatrics, Normandie Univ, UNIROUEN, INSERM U1245, and Rouen University Hospital, Rouen, France; Normal and Pathological Glutamatergic Systems, Neuroscience Paris Seine, IBPS, INSERM U1130, CNRS UMR 8246 Université Pierre et Marie Curie, Paris, France; INSERM U1088, Laboratoire de Biochimie, Centre de Biologie Humaine, Amiens-Picardie University Hospital, Amiens, France; Normandie Univ, UNIROUEN, PSY-NCA, Rouen, France
| |
Collapse
|
20
|
Tebani A, Schmitz-Afonso I, Abily-Donval L, Héron B, Piraud M, Ausseil J, Brassier A, De Lonlay P, Zerimech F, Vaz FM, Gonzalez BJ, Marret S, Afonso C, Bekri S. Urinary metabolic phenotyping of mucopolysaccharidosis type I combining untargeted and targeted strategies with data modeling. Clin Chim Acta 2017; 475:7-14. [PMID: 28982054 DOI: 10.1016/j.cca.2017.09.024] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2017] [Revised: 09/29/2017] [Accepted: 09/30/2017] [Indexed: 12/14/2022]
Abstract
BACKGROUND Application of metabolic phenotyping could expand the pathophysiological knowledge of mucopolysaccharidoses (MPS) and may reveal the comprehensive metabolic impairments in MPS. However, few studies applied this approach to MPS. METHODS We applied targeted and untargeted metabolic profiling in urine samples obtained from a French cohort comprising 19 MPS I and 15 MPS I treated patients along with 66 controls. For that purpose, we used ultra-high-performance liquid chromatography combined with ion mobility and high-resolution mass spectrometry following a protocol designed for large-scale metabolomics studies regarding robustness and reproducibility. Furthermore, 24 amino acids have been quantified using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). Keratan sulfate, Heparan sulfate and Dermatan sulfate concentrations have also been measured using an LC-MS/MS method. Univariate and multivariate data analyses have been used to select discriminant metabolites. The mummichog algorithm has been used for pathway analysis. RESULTS The studied groups yielded distinct biochemical phenotypes using multivariate data analysis. Univariate statistics also revealed metabolites that differentiated the groups. Specifically, metabolites related to the amino acid metabolism. Pathway analysis revealed that several major amino acid pathways were dysregulated in MPS. Comparison of targeted and untargeted metabolomics data with in silico results yielded arginine, proline and glutathione metabolisms being the most affected. CONCLUSION This study is one of the first metabolic phenotyping studies of MPS I. The findings might help to generate new hypotheses about MPS pathophysiology and to develop further targeted studies of a smaller number of potentially key metabolites.
Collapse
Affiliation(s)
- Abdellah Tebani
- Department of Metabolic Biochemistry, Rouen University Hospital, Rouen 76000, France; Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000 Rouen, France; Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA, 76000 Rouen, France
| | | | - Lenaig Abily-Donval
- Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000 Rouen, France; Department of Neonatal Pediatrics and Intensive Care, Rouen University Hospital, Rouen 76031, France
| | - Bénédicte Héron
- Departement of Pediatric Neurology, Reference Center of Lysosomal Diseases, Trousseau Hospital, APHP, GRC ConCer-LD, Sorbonne Universities, UPMC University 06, Paris, France
| | - Monique Piraud
- Service de Biochimie et Biologie Moléculaire Grand Est, Unité des Maladies Héréditaires du Métabolisme et Dépistage Néonatal, Centre de Biologie et de Pathologie Est CHU de Lyon, Lyon, France
| | - Jérôme Ausseil
- INSERM U1088, Laboratoire de Biochimie Métabolique, Centre de Biologie Humaine, CHU Sud, 80054 Amiens Cedex, France
| | - Anais Brassier
- Reference Center of Inherited Metabolic Diseases, Imagine Institute, Hospital Necker Enfants Malades, APHP, University Paris Descartes, Paris, France
| | - Pascale De Lonlay
- Reference Center of Inherited Metabolic Diseases, Imagine Institute, Hospital Necker Enfants Malades, APHP, University Paris Descartes, Paris, France
| | - Farid Zerimech
- Laboratoire de Biochimie et Biologie Moléculaire, Université de Lille et Pôle de Biologie Pathologie Génétique du CHRU de Lille, 59000 Lille, France
| | - Frédéric M Vaz
- Laboratory of Genetic Metabolic Diseases, Department of Clinical Chemistry and Pediatrics, Academic Medical Center, Amsterdam, The Netherlands
| | - Bruno J Gonzalez
- Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000 Rouen, France
| | - Stephane Marret
- Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000 Rouen, France; Department of Neonatal Pediatrics and Intensive Care, Rouen University Hospital, Rouen 76031, France
| | - Carlos Afonso
- Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA, 76000 Rouen, France
| | - Soumeya Bekri
- Department of Metabolic Biochemistry, Rouen University Hospital, Rouen 76000, France; Normandie Univ, UNIROUEN, CHU Rouen, INSERM U1245, 76000 Rouen, France.
| |
Collapse
|
21
|
Hodroge A, Trécherel E, Cornu M, Darwiche W, Mansour A, Ait-Mohand K, Verissimo T, Gomila C, Schembri C, Da Nascimento S, Elboutachfaiti R, Boullier A, Lorne E, Courtois J, Petit E, Toumieux S, Kovensky J, Sonnet P, Massy ZA, Kamel S, Rossi C, Ausseil J. Oligogalacturonic Acid Inhibits Vascular Calcification by Two Mechanisms: Inhibition of Vascular Smooth Muscle Cell Osteogenic Conversion and Interaction With Collagen. Arterioscler Thromb Vasc Biol 2017; 37:1391-1401. [PMID: 28522698 DOI: 10.1161/atvbaha.117.309513] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2016] [Accepted: 05/03/2017] [Indexed: 12/12/2022]
Abstract
OBJECTIVE Cardiovascular diseases constitute the leading cause of mortality worldwide. Calcification of the vessel wall is associated with cardiovascular morbidity and mortality in patients having many diseases, including diabetes mellitus, atherosclerosis, and chronic kidney disease. Vascular calcification is actively regulated by inductive and inhibitory mechanisms (including vascular smooth muscle cell adaptation) and results from an active osteogenic process. During the calcification process, extracellular vesicles (also known as matrix vesicles) released by vascular smooth muscle cells interact with type I collagen and then act as nucleating foci for calcium crystallization. Our primary objective was to identify new, natural molecules that inhibit the vascular calcification process. APPROACH AND RESULTS We have found that oligogalacturonic acids (obtained by the acid hydrolysis of polygalacturonic acid) reduce in vitro inorganic phosphate-induced calcification of vascular smooth muscle cells by 80% and inorganic phosphate-induced calcification of isolated rat aortic rings by 50%. A specific oligogalacturonic acid with a degree of polymerization of 8 (DP8) was found to inhibit the expression of osteogenic markers and, thus, prevent the conversion of vascular smooth muscle cells into osteoblast-like cells. We also evidenced in biochemical and immunofluorescence assays a direct interaction between matrix vesicles and type I collagen via the GFOGER sequence (where single letter amino acid nomenclature is used, O=hydroxyproline) thought to be involved in interactions with several pairs of integrins. CONCLUSIONS DP8 inhibits vascular calcification development mainly by inhibition of osteogenic marker expression but also partly by masking the GFOGER sequence-thereby, preventing matrix vesicles from binding to type I collagen.
Collapse
Affiliation(s)
- Ahmed Hodroge
- From the Unité INSERM U1088, CURS-Université de Picardie Jules Verne, Amiens, France (A.H., E.T., M.C., W.D., A.M., T.V., C.G., A.B., E.L., S.K., J.A.); Laboratoire de Biochimie, CHU Amiens, France (A.H., E.T., C.G., A.B., S.K., J.A.); Laboratoire de Glycochimie, des Antimicrobiens et des Agroressources LG2A UMR 7378, Université de Picardie Jules Verne, Amiens, France (K.A.-M., S.T., J.K.); Laboratoire des polysaccharides microbiens et végétaux EA3900-BIOPI, IUT Université de Picardie Jules Verne, Avenue des Facultés, Le Bailly, Amiens, France (R.E., J.C., E.P.); Sorbonne universités, Université de Technologie de Compiègne, CNRS, Laboratoire de Génie enzymatique et cellulaire, Rue Roger Couttolenc, CS 60319, Compiègne Cedex, France (C.S., C.R.); Laboratoire de Glycochimie des Antimicrobiens et des Agroressources, LG2A UMR 7378, Université de Picardie Jules Verne, Amiens Cedex 1, France (S.D.N., P.S.); and Service de Nephrologie, Hôpital Ambroise Paré, Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt/Paris, Université Paris Ouest-Versailles-Saint-Quentin-en-Yvelines (UVSQ) et Inserm U1018, Equipe 5, CESP, Villejuif, France (Z.A.M.)
| | - Eric Trécherel
- From the Unité INSERM U1088, CURS-Université de Picardie Jules Verne, Amiens, France (A.H., E.T., M.C., W.D., A.M., T.V., C.G., A.B., E.L., S.K., J.A.); Laboratoire de Biochimie, CHU Amiens, France (A.H., E.T., C.G., A.B., S.K., J.A.); Laboratoire de Glycochimie, des Antimicrobiens et des Agroressources LG2A UMR 7378, Université de Picardie Jules Verne, Amiens, France (K.A.-M., S.T., J.K.); Laboratoire des polysaccharides microbiens et végétaux EA3900-BIOPI, IUT Université de Picardie Jules Verne, Avenue des Facultés, Le Bailly, Amiens, France (R.E., J.C., E.P.); Sorbonne universités, Université de Technologie de Compiègne, CNRS, Laboratoire de Génie enzymatique et cellulaire, Rue Roger Couttolenc, CS 60319, Compiègne Cedex, France (C.S., C.R.); Laboratoire de Glycochimie des Antimicrobiens et des Agroressources, LG2A UMR 7378, Université de Picardie Jules Verne, Amiens Cedex 1, France (S.D.N., P.S.); and Service de Nephrologie, Hôpital Ambroise Paré, Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt/Paris, Université Paris Ouest-Versailles-Saint-Quentin-en-Yvelines (UVSQ) et Inserm U1018, Equipe 5, CESP, Villejuif, France (Z.A.M.)
| | - Marjorie Cornu
- From the Unité INSERM U1088, CURS-Université de Picardie Jules Verne, Amiens, France (A.H., E.T., M.C., W.D., A.M., T.V., C.G., A.B., E.L., S.K., J.A.); Laboratoire de Biochimie, CHU Amiens, France (A.H., E.T., C.G., A.B., S.K., J.A.); Laboratoire de Glycochimie, des Antimicrobiens et des Agroressources LG2A UMR 7378, Université de Picardie Jules Verne, Amiens, France (K.A.-M., S.T., J.K.); Laboratoire des polysaccharides microbiens et végétaux EA3900-BIOPI, IUT Université de Picardie Jules Verne, Avenue des Facultés, Le Bailly, Amiens, France (R.E., J.C., E.P.); Sorbonne universités, Université de Technologie de Compiègne, CNRS, Laboratoire de Génie enzymatique et cellulaire, Rue Roger Couttolenc, CS 60319, Compiègne Cedex, France (C.S., C.R.); Laboratoire de Glycochimie des Antimicrobiens et des Agroressources, LG2A UMR 7378, Université de Picardie Jules Verne, Amiens Cedex 1, France (S.D.N., P.S.); and Service de Nephrologie, Hôpital Ambroise Paré, Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt/Paris, Université Paris Ouest-Versailles-Saint-Quentin-en-Yvelines (UVSQ) et Inserm U1018, Equipe 5, CESP, Villejuif, France (Z.A.M.)
| | - Walaa Darwiche
- From the Unité INSERM U1088, CURS-Université de Picardie Jules Verne, Amiens, France (A.H., E.T., M.C., W.D., A.M., T.V., C.G., A.B., E.L., S.K., J.A.); Laboratoire de Biochimie, CHU Amiens, France (A.H., E.T., C.G., A.B., S.K., J.A.); Laboratoire de Glycochimie, des Antimicrobiens et des Agroressources LG2A UMR 7378, Université de Picardie Jules Verne, Amiens, France (K.A.-M., S.T., J.K.); Laboratoire des polysaccharides microbiens et végétaux EA3900-BIOPI, IUT Université de Picardie Jules Verne, Avenue des Facultés, Le Bailly, Amiens, France (R.E., J.C., E.P.); Sorbonne universités, Université de Technologie de Compiègne, CNRS, Laboratoire de Génie enzymatique et cellulaire, Rue Roger Couttolenc, CS 60319, Compiègne Cedex, France (C.S., C.R.); Laboratoire de Glycochimie des Antimicrobiens et des Agroressources, LG2A UMR 7378, Université de Picardie Jules Verne, Amiens Cedex 1, France (S.D.N., P.S.); and Service de Nephrologie, Hôpital Ambroise Paré, Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt/Paris, Université Paris Ouest-Versailles-Saint-Quentin-en-Yvelines (UVSQ) et Inserm U1018, Equipe 5, CESP, Villejuif, France (Z.A.M.)
| | - Ali Mansour
- From the Unité INSERM U1088, CURS-Université de Picardie Jules Verne, Amiens, France (A.H., E.T., M.C., W.D., A.M., T.V., C.G., A.B., E.L., S.K., J.A.); Laboratoire de Biochimie, CHU Amiens, France (A.H., E.T., C.G., A.B., S.K., J.A.); Laboratoire de Glycochimie, des Antimicrobiens et des Agroressources LG2A UMR 7378, Université de Picardie Jules Verne, Amiens, France (K.A.-M., S.T., J.K.); Laboratoire des polysaccharides microbiens et végétaux EA3900-BIOPI, IUT Université de Picardie Jules Verne, Avenue des Facultés, Le Bailly, Amiens, France (R.E., J.C., E.P.); Sorbonne universités, Université de Technologie de Compiègne, CNRS, Laboratoire de Génie enzymatique et cellulaire, Rue Roger Couttolenc, CS 60319, Compiègne Cedex, France (C.S., C.R.); Laboratoire de Glycochimie des Antimicrobiens et des Agroressources, LG2A UMR 7378, Université de Picardie Jules Verne, Amiens Cedex 1, France (S.D.N., P.S.); and Service de Nephrologie, Hôpital Ambroise Paré, Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt/Paris, Université Paris Ouest-Versailles-Saint-Quentin-en-Yvelines (UVSQ) et Inserm U1018, Equipe 5, CESP, Villejuif, France (Z.A.M.)
| | - Katia Ait-Mohand
- From the Unité INSERM U1088, CURS-Université de Picardie Jules Verne, Amiens, France (A.H., E.T., M.C., W.D., A.M., T.V., C.G., A.B., E.L., S.K., J.A.); Laboratoire de Biochimie, CHU Amiens, France (A.H., E.T., C.G., A.B., S.K., J.A.); Laboratoire de Glycochimie, des Antimicrobiens et des Agroressources LG2A UMR 7378, Université de Picardie Jules Verne, Amiens, France (K.A.-M., S.T., J.K.); Laboratoire des polysaccharides microbiens et végétaux EA3900-BIOPI, IUT Université de Picardie Jules Verne, Avenue des Facultés, Le Bailly, Amiens, France (R.E., J.C., E.P.); Sorbonne universités, Université de Technologie de Compiègne, CNRS, Laboratoire de Génie enzymatique et cellulaire, Rue Roger Couttolenc, CS 60319, Compiègne Cedex, France (C.S., C.R.); Laboratoire de Glycochimie des Antimicrobiens et des Agroressources, LG2A UMR 7378, Université de Picardie Jules Verne, Amiens Cedex 1, France (S.D.N., P.S.); and Service de Nephrologie, Hôpital Ambroise Paré, Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt/Paris, Université Paris Ouest-Versailles-Saint-Quentin-en-Yvelines (UVSQ) et Inserm U1018, Equipe 5, CESP, Villejuif, France (Z.A.M.)
| | - Thomas Verissimo
- From the Unité INSERM U1088, CURS-Université de Picardie Jules Verne, Amiens, France (A.H., E.T., M.C., W.D., A.M., T.V., C.G., A.B., E.L., S.K., J.A.); Laboratoire de Biochimie, CHU Amiens, France (A.H., E.T., C.G., A.B., S.K., J.A.); Laboratoire de Glycochimie, des Antimicrobiens et des Agroressources LG2A UMR 7378, Université de Picardie Jules Verne, Amiens, France (K.A.-M., S.T., J.K.); Laboratoire des polysaccharides microbiens et végétaux EA3900-BIOPI, IUT Université de Picardie Jules Verne, Avenue des Facultés, Le Bailly, Amiens, France (R.E., J.C., E.P.); Sorbonne universités, Université de Technologie de Compiègne, CNRS, Laboratoire de Génie enzymatique et cellulaire, Rue Roger Couttolenc, CS 60319, Compiègne Cedex, France (C.S., C.R.); Laboratoire de Glycochimie des Antimicrobiens et des Agroressources, LG2A UMR 7378, Université de Picardie Jules Verne, Amiens Cedex 1, France (S.D.N., P.S.); and Service de Nephrologie, Hôpital Ambroise Paré, Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt/Paris, Université Paris Ouest-Versailles-Saint-Quentin-en-Yvelines (UVSQ) et Inserm U1018, Equipe 5, CESP, Villejuif, France (Z.A.M.)
| | - Cathy Gomila
- From the Unité INSERM U1088, CURS-Université de Picardie Jules Verne, Amiens, France (A.H., E.T., M.C., W.D., A.M., T.V., C.G., A.B., E.L., S.K., J.A.); Laboratoire de Biochimie, CHU Amiens, France (A.H., E.T., C.G., A.B., S.K., J.A.); Laboratoire de Glycochimie, des Antimicrobiens et des Agroressources LG2A UMR 7378, Université de Picardie Jules Verne, Amiens, France (K.A.-M., S.T., J.K.); Laboratoire des polysaccharides microbiens et végétaux EA3900-BIOPI, IUT Université de Picardie Jules Verne, Avenue des Facultés, Le Bailly, Amiens, France (R.E., J.C., E.P.); Sorbonne universités, Université de Technologie de Compiègne, CNRS, Laboratoire de Génie enzymatique et cellulaire, Rue Roger Couttolenc, CS 60319, Compiègne Cedex, France (C.S., C.R.); Laboratoire de Glycochimie des Antimicrobiens et des Agroressources, LG2A UMR 7378, Université de Picardie Jules Verne, Amiens Cedex 1, France (S.D.N., P.S.); and Service de Nephrologie, Hôpital Ambroise Paré, Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt/Paris, Université Paris Ouest-Versailles-Saint-Quentin-en-Yvelines (UVSQ) et Inserm U1018, Equipe 5, CESP, Villejuif, France (Z.A.M.)
| | - Carole Schembri
- From the Unité INSERM U1088, CURS-Université de Picardie Jules Verne, Amiens, France (A.H., E.T., M.C., W.D., A.M., T.V., C.G., A.B., E.L., S.K., J.A.); Laboratoire de Biochimie, CHU Amiens, France (A.H., E.T., C.G., A.B., S.K., J.A.); Laboratoire de Glycochimie, des Antimicrobiens et des Agroressources LG2A UMR 7378, Université de Picardie Jules Verne, Amiens, France (K.A.-M., S.T., J.K.); Laboratoire des polysaccharides microbiens et végétaux EA3900-BIOPI, IUT Université de Picardie Jules Verne, Avenue des Facultés, Le Bailly, Amiens, France (R.E., J.C., E.P.); Sorbonne universités, Université de Technologie de Compiègne, CNRS, Laboratoire de Génie enzymatique et cellulaire, Rue Roger Couttolenc, CS 60319, Compiègne Cedex, France (C.S., C.R.); Laboratoire de Glycochimie des Antimicrobiens et des Agroressources, LG2A UMR 7378, Université de Picardie Jules Verne, Amiens Cedex 1, France (S.D.N., P.S.); and Service de Nephrologie, Hôpital Ambroise Paré, Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt/Paris, Université Paris Ouest-Versailles-Saint-Quentin-en-Yvelines (UVSQ) et Inserm U1018, Equipe 5, CESP, Villejuif, France (Z.A.M.)
| | - Sophie Da Nascimento
- From the Unité INSERM U1088, CURS-Université de Picardie Jules Verne, Amiens, France (A.H., E.T., M.C., W.D., A.M., T.V., C.G., A.B., E.L., S.K., J.A.); Laboratoire de Biochimie, CHU Amiens, France (A.H., E.T., C.G., A.B., S.K., J.A.); Laboratoire de Glycochimie, des Antimicrobiens et des Agroressources LG2A UMR 7378, Université de Picardie Jules Verne, Amiens, France (K.A.-M., S.T., J.K.); Laboratoire des polysaccharides microbiens et végétaux EA3900-BIOPI, IUT Université de Picardie Jules Verne, Avenue des Facultés, Le Bailly, Amiens, France (R.E., J.C., E.P.); Sorbonne universités, Université de Technologie de Compiègne, CNRS, Laboratoire de Génie enzymatique et cellulaire, Rue Roger Couttolenc, CS 60319, Compiègne Cedex, France (C.S., C.R.); Laboratoire de Glycochimie des Antimicrobiens et des Agroressources, LG2A UMR 7378, Université de Picardie Jules Verne, Amiens Cedex 1, France (S.D.N., P.S.); and Service de Nephrologie, Hôpital Ambroise Paré, Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt/Paris, Université Paris Ouest-Versailles-Saint-Quentin-en-Yvelines (UVSQ) et Inserm U1018, Equipe 5, CESP, Villejuif, France (Z.A.M.)
| | - Redouan Elboutachfaiti
- From the Unité INSERM U1088, CURS-Université de Picardie Jules Verne, Amiens, France (A.H., E.T., M.C., W.D., A.M., T.V., C.G., A.B., E.L., S.K., J.A.); Laboratoire de Biochimie, CHU Amiens, France (A.H., E.T., C.G., A.B., S.K., J.A.); Laboratoire de Glycochimie, des Antimicrobiens et des Agroressources LG2A UMR 7378, Université de Picardie Jules Verne, Amiens, France (K.A.-M., S.T., J.K.); Laboratoire des polysaccharides microbiens et végétaux EA3900-BIOPI, IUT Université de Picardie Jules Verne, Avenue des Facultés, Le Bailly, Amiens, France (R.E., J.C., E.P.); Sorbonne universités, Université de Technologie de Compiègne, CNRS, Laboratoire de Génie enzymatique et cellulaire, Rue Roger Couttolenc, CS 60319, Compiègne Cedex, France (C.S., C.R.); Laboratoire de Glycochimie des Antimicrobiens et des Agroressources, LG2A UMR 7378, Université de Picardie Jules Verne, Amiens Cedex 1, France (S.D.N., P.S.); and Service de Nephrologie, Hôpital Ambroise Paré, Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt/Paris, Université Paris Ouest-Versailles-Saint-Quentin-en-Yvelines (UVSQ) et Inserm U1018, Equipe 5, CESP, Villejuif, France (Z.A.M.)
| | - Agnès Boullier
- From the Unité INSERM U1088, CURS-Université de Picardie Jules Verne, Amiens, France (A.H., E.T., M.C., W.D., A.M., T.V., C.G., A.B., E.L., S.K., J.A.); Laboratoire de Biochimie, CHU Amiens, France (A.H., E.T., C.G., A.B., S.K., J.A.); Laboratoire de Glycochimie, des Antimicrobiens et des Agroressources LG2A UMR 7378, Université de Picardie Jules Verne, Amiens, France (K.A.-M., S.T., J.K.); Laboratoire des polysaccharides microbiens et végétaux EA3900-BIOPI, IUT Université de Picardie Jules Verne, Avenue des Facultés, Le Bailly, Amiens, France (R.E., J.C., E.P.); Sorbonne universités, Université de Technologie de Compiègne, CNRS, Laboratoire de Génie enzymatique et cellulaire, Rue Roger Couttolenc, CS 60319, Compiègne Cedex, France (C.S., C.R.); Laboratoire de Glycochimie des Antimicrobiens et des Agroressources, LG2A UMR 7378, Université de Picardie Jules Verne, Amiens Cedex 1, France (S.D.N., P.S.); and Service de Nephrologie, Hôpital Ambroise Paré, Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt/Paris, Université Paris Ouest-Versailles-Saint-Quentin-en-Yvelines (UVSQ) et Inserm U1018, Equipe 5, CESP, Villejuif, France (Z.A.M.)
| | - Emmanuel Lorne
- From the Unité INSERM U1088, CURS-Université de Picardie Jules Verne, Amiens, France (A.H., E.T., M.C., W.D., A.M., T.V., C.G., A.B., E.L., S.K., J.A.); Laboratoire de Biochimie, CHU Amiens, France (A.H., E.T., C.G., A.B., S.K., J.A.); Laboratoire de Glycochimie, des Antimicrobiens et des Agroressources LG2A UMR 7378, Université de Picardie Jules Verne, Amiens, France (K.A.-M., S.T., J.K.); Laboratoire des polysaccharides microbiens et végétaux EA3900-BIOPI, IUT Université de Picardie Jules Verne, Avenue des Facultés, Le Bailly, Amiens, France (R.E., J.C., E.P.); Sorbonne universités, Université de Technologie de Compiègne, CNRS, Laboratoire de Génie enzymatique et cellulaire, Rue Roger Couttolenc, CS 60319, Compiègne Cedex, France (C.S., C.R.); Laboratoire de Glycochimie des Antimicrobiens et des Agroressources, LG2A UMR 7378, Université de Picardie Jules Verne, Amiens Cedex 1, France (S.D.N., P.S.); and Service de Nephrologie, Hôpital Ambroise Paré, Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt/Paris, Université Paris Ouest-Versailles-Saint-Quentin-en-Yvelines (UVSQ) et Inserm U1018, Equipe 5, CESP, Villejuif, France (Z.A.M.)
| | - Josiane Courtois
- From the Unité INSERM U1088, CURS-Université de Picardie Jules Verne, Amiens, France (A.H., E.T., M.C., W.D., A.M., T.V., C.G., A.B., E.L., S.K., J.A.); Laboratoire de Biochimie, CHU Amiens, France (A.H., E.T., C.G., A.B., S.K., J.A.); Laboratoire de Glycochimie, des Antimicrobiens et des Agroressources LG2A UMR 7378, Université de Picardie Jules Verne, Amiens, France (K.A.-M., S.T., J.K.); Laboratoire des polysaccharides microbiens et végétaux EA3900-BIOPI, IUT Université de Picardie Jules Verne, Avenue des Facultés, Le Bailly, Amiens, France (R.E., J.C., E.P.); Sorbonne universités, Université de Technologie de Compiègne, CNRS, Laboratoire de Génie enzymatique et cellulaire, Rue Roger Couttolenc, CS 60319, Compiègne Cedex, France (C.S., C.R.); Laboratoire de Glycochimie des Antimicrobiens et des Agroressources, LG2A UMR 7378, Université de Picardie Jules Verne, Amiens Cedex 1, France (S.D.N., P.S.); and Service de Nephrologie, Hôpital Ambroise Paré, Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt/Paris, Université Paris Ouest-Versailles-Saint-Quentin-en-Yvelines (UVSQ) et Inserm U1018, Equipe 5, CESP, Villejuif, France (Z.A.M.)
| | - Emmanuel Petit
- From the Unité INSERM U1088, CURS-Université de Picardie Jules Verne, Amiens, France (A.H., E.T., M.C., W.D., A.M., T.V., C.G., A.B., E.L., S.K., J.A.); Laboratoire de Biochimie, CHU Amiens, France (A.H., E.T., C.G., A.B., S.K., J.A.); Laboratoire de Glycochimie, des Antimicrobiens et des Agroressources LG2A UMR 7378, Université de Picardie Jules Verne, Amiens, France (K.A.-M., S.T., J.K.); Laboratoire des polysaccharides microbiens et végétaux EA3900-BIOPI, IUT Université de Picardie Jules Verne, Avenue des Facultés, Le Bailly, Amiens, France (R.E., J.C., E.P.); Sorbonne universités, Université de Technologie de Compiègne, CNRS, Laboratoire de Génie enzymatique et cellulaire, Rue Roger Couttolenc, CS 60319, Compiègne Cedex, France (C.S., C.R.); Laboratoire de Glycochimie des Antimicrobiens et des Agroressources, LG2A UMR 7378, Université de Picardie Jules Verne, Amiens Cedex 1, France (S.D.N., P.S.); and Service de Nephrologie, Hôpital Ambroise Paré, Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt/Paris, Université Paris Ouest-Versailles-Saint-Quentin-en-Yvelines (UVSQ) et Inserm U1018, Equipe 5, CESP, Villejuif, France (Z.A.M.)
| | - Sylvestre Toumieux
- From the Unité INSERM U1088, CURS-Université de Picardie Jules Verne, Amiens, France (A.H., E.T., M.C., W.D., A.M., T.V., C.G., A.B., E.L., S.K., J.A.); Laboratoire de Biochimie, CHU Amiens, France (A.H., E.T., C.G., A.B., S.K., J.A.); Laboratoire de Glycochimie, des Antimicrobiens et des Agroressources LG2A UMR 7378, Université de Picardie Jules Verne, Amiens, France (K.A.-M., S.T., J.K.); Laboratoire des polysaccharides microbiens et végétaux EA3900-BIOPI, IUT Université de Picardie Jules Verne, Avenue des Facultés, Le Bailly, Amiens, France (R.E., J.C., E.P.); Sorbonne universités, Université de Technologie de Compiègne, CNRS, Laboratoire de Génie enzymatique et cellulaire, Rue Roger Couttolenc, CS 60319, Compiègne Cedex, France (C.S., C.R.); Laboratoire de Glycochimie des Antimicrobiens et des Agroressources, LG2A UMR 7378, Université de Picardie Jules Verne, Amiens Cedex 1, France (S.D.N., P.S.); and Service de Nephrologie, Hôpital Ambroise Paré, Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt/Paris, Université Paris Ouest-Versailles-Saint-Quentin-en-Yvelines (UVSQ) et Inserm U1018, Equipe 5, CESP, Villejuif, France (Z.A.M.)
| | - José Kovensky
- From the Unité INSERM U1088, CURS-Université de Picardie Jules Verne, Amiens, France (A.H., E.T., M.C., W.D., A.M., T.V., C.G., A.B., E.L., S.K., J.A.); Laboratoire de Biochimie, CHU Amiens, France (A.H., E.T., C.G., A.B., S.K., J.A.); Laboratoire de Glycochimie, des Antimicrobiens et des Agroressources LG2A UMR 7378, Université de Picardie Jules Verne, Amiens, France (K.A.-M., S.T., J.K.); Laboratoire des polysaccharides microbiens et végétaux EA3900-BIOPI, IUT Université de Picardie Jules Verne, Avenue des Facultés, Le Bailly, Amiens, France (R.E., J.C., E.P.); Sorbonne universités, Université de Technologie de Compiègne, CNRS, Laboratoire de Génie enzymatique et cellulaire, Rue Roger Couttolenc, CS 60319, Compiègne Cedex, France (C.S., C.R.); Laboratoire de Glycochimie des Antimicrobiens et des Agroressources, LG2A UMR 7378, Université de Picardie Jules Verne, Amiens Cedex 1, France (S.D.N., P.S.); and Service de Nephrologie, Hôpital Ambroise Paré, Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt/Paris, Université Paris Ouest-Versailles-Saint-Quentin-en-Yvelines (UVSQ) et Inserm U1018, Equipe 5, CESP, Villejuif, France (Z.A.M.)
| | - Pascal Sonnet
- From the Unité INSERM U1088, CURS-Université de Picardie Jules Verne, Amiens, France (A.H., E.T., M.C., W.D., A.M., T.V., C.G., A.B., E.L., S.K., J.A.); Laboratoire de Biochimie, CHU Amiens, France (A.H., E.T., C.G., A.B., S.K., J.A.); Laboratoire de Glycochimie, des Antimicrobiens et des Agroressources LG2A UMR 7378, Université de Picardie Jules Verne, Amiens, France (K.A.-M., S.T., J.K.); Laboratoire des polysaccharides microbiens et végétaux EA3900-BIOPI, IUT Université de Picardie Jules Verne, Avenue des Facultés, Le Bailly, Amiens, France (R.E., J.C., E.P.); Sorbonne universités, Université de Technologie de Compiègne, CNRS, Laboratoire de Génie enzymatique et cellulaire, Rue Roger Couttolenc, CS 60319, Compiègne Cedex, France (C.S., C.R.); Laboratoire de Glycochimie des Antimicrobiens et des Agroressources, LG2A UMR 7378, Université de Picardie Jules Verne, Amiens Cedex 1, France (S.D.N., P.S.); and Service de Nephrologie, Hôpital Ambroise Paré, Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt/Paris, Université Paris Ouest-Versailles-Saint-Quentin-en-Yvelines (UVSQ) et Inserm U1018, Equipe 5, CESP, Villejuif, France (Z.A.M.)
| | - Ziad A Massy
- From the Unité INSERM U1088, CURS-Université de Picardie Jules Verne, Amiens, France (A.H., E.T., M.C., W.D., A.M., T.V., C.G., A.B., E.L., S.K., J.A.); Laboratoire de Biochimie, CHU Amiens, France (A.H., E.T., C.G., A.B., S.K., J.A.); Laboratoire de Glycochimie, des Antimicrobiens et des Agroressources LG2A UMR 7378, Université de Picardie Jules Verne, Amiens, France (K.A.-M., S.T., J.K.); Laboratoire des polysaccharides microbiens et végétaux EA3900-BIOPI, IUT Université de Picardie Jules Verne, Avenue des Facultés, Le Bailly, Amiens, France (R.E., J.C., E.P.); Sorbonne universités, Université de Technologie de Compiègne, CNRS, Laboratoire de Génie enzymatique et cellulaire, Rue Roger Couttolenc, CS 60319, Compiègne Cedex, France (C.S., C.R.); Laboratoire de Glycochimie des Antimicrobiens et des Agroressources, LG2A UMR 7378, Université de Picardie Jules Verne, Amiens Cedex 1, France (S.D.N., P.S.); and Service de Nephrologie, Hôpital Ambroise Paré, Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt/Paris, Université Paris Ouest-Versailles-Saint-Quentin-en-Yvelines (UVSQ) et Inserm U1018, Equipe 5, CESP, Villejuif, France (Z.A.M.)
| | - Saïd Kamel
- From the Unité INSERM U1088, CURS-Université de Picardie Jules Verne, Amiens, France (A.H., E.T., M.C., W.D., A.M., T.V., C.G., A.B., E.L., S.K., J.A.); Laboratoire de Biochimie, CHU Amiens, France (A.H., E.T., C.G., A.B., S.K., J.A.); Laboratoire de Glycochimie, des Antimicrobiens et des Agroressources LG2A UMR 7378, Université de Picardie Jules Verne, Amiens, France (K.A.-M., S.T., J.K.); Laboratoire des polysaccharides microbiens et végétaux EA3900-BIOPI, IUT Université de Picardie Jules Verne, Avenue des Facultés, Le Bailly, Amiens, France (R.E., J.C., E.P.); Sorbonne universités, Université de Technologie de Compiègne, CNRS, Laboratoire de Génie enzymatique et cellulaire, Rue Roger Couttolenc, CS 60319, Compiègne Cedex, France (C.S., C.R.); Laboratoire de Glycochimie des Antimicrobiens et des Agroressources, LG2A UMR 7378, Université de Picardie Jules Verne, Amiens Cedex 1, France (S.D.N., P.S.); and Service de Nephrologie, Hôpital Ambroise Paré, Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt/Paris, Université Paris Ouest-Versailles-Saint-Quentin-en-Yvelines (UVSQ) et Inserm U1018, Equipe 5, CESP, Villejuif, France (Z.A.M.)
| | - Claire Rossi
- From the Unité INSERM U1088, CURS-Université de Picardie Jules Verne, Amiens, France (A.H., E.T., M.C., W.D., A.M., T.V., C.G., A.B., E.L., S.K., J.A.); Laboratoire de Biochimie, CHU Amiens, France (A.H., E.T., C.G., A.B., S.K., J.A.); Laboratoire de Glycochimie, des Antimicrobiens et des Agroressources LG2A UMR 7378, Université de Picardie Jules Verne, Amiens, France (K.A.-M., S.T., J.K.); Laboratoire des polysaccharides microbiens et végétaux EA3900-BIOPI, IUT Université de Picardie Jules Verne, Avenue des Facultés, Le Bailly, Amiens, France (R.E., J.C., E.P.); Sorbonne universités, Université de Technologie de Compiègne, CNRS, Laboratoire de Génie enzymatique et cellulaire, Rue Roger Couttolenc, CS 60319, Compiègne Cedex, France (C.S., C.R.); Laboratoire de Glycochimie des Antimicrobiens et des Agroressources, LG2A UMR 7378, Université de Picardie Jules Verne, Amiens Cedex 1, France (S.D.N., P.S.); and Service de Nephrologie, Hôpital Ambroise Paré, Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt/Paris, Université Paris Ouest-Versailles-Saint-Quentin-en-Yvelines (UVSQ) et Inserm U1018, Equipe 5, CESP, Villejuif, France (Z.A.M.)
| | - Jérôme Ausseil
- From the Unité INSERM U1088, CURS-Université de Picardie Jules Verne, Amiens, France (A.H., E.T., M.C., W.D., A.M., T.V., C.G., A.B., E.L., S.K., J.A.); Laboratoire de Biochimie, CHU Amiens, France (A.H., E.T., C.G., A.B., S.K., J.A.); Laboratoire de Glycochimie, des Antimicrobiens et des Agroressources LG2A UMR 7378, Université de Picardie Jules Verne, Amiens, France (K.A.-M., S.T., J.K.); Laboratoire des polysaccharides microbiens et végétaux EA3900-BIOPI, IUT Université de Picardie Jules Verne, Avenue des Facultés, Le Bailly, Amiens, France (R.E., J.C., E.P.); Sorbonne universités, Université de Technologie de Compiègne, CNRS, Laboratoire de Génie enzymatique et cellulaire, Rue Roger Couttolenc, CS 60319, Compiègne Cedex, France (C.S., C.R.); Laboratoire de Glycochimie des Antimicrobiens et des Agroressources, LG2A UMR 7378, Université de Picardie Jules Verne, Amiens Cedex 1, France (S.D.N., P.S.); and Service de Nephrologie, Hôpital Ambroise Paré, Assistance Publique Hôpitaux de Paris, Boulogne-Billancourt/Paris, Université Paris Ouest-Versailles-Saint-Quentin-en-Yvelines (UVSQ) et Inserm U1018, Equipe 5, CESP, Villejuif, France (Z.A.M.).
| |
Collapse
|
22
|
Bruyère J, Roy E, Ausseil J, Lemonnier T, Teyre G, Bohl D, Etienne-Manneville S, Lortat-Jacob H, Heard JM, Vitry S. Heparan Sulfate Saccharides Modify Focal Adhesions: Implication in Mucopolysaccharidosis Neuropathophysiology. J Mol Biol 2015; 427:775-791. [DOI: 10.1016/j.jmb.2014.09.012] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2014] [Revised: 09/18/2014] [Accepted: 09/24/2014] [Indexed: 10/24/2022]
|
23
|
Trudel S, Trécherel E, Gomila C, Peltier M, Aubignat M, Gubler B, Morlière P, Heard JM, Ausseil J. Oxidative stress is independent of inflammation in the neurodegenerative Sanfilippo syndrome type B. J Neurosci Res 2014; 93:424-32. [PMID: 25332157 DOI: 10.1002/jnr.23497] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2014] [Accepted: 09/15/2014] [Indexed: 01/22/2023]
Abstract
Mucopolysaccharidosis (MPS) type IIIB is a genetic deficiency of α-N-acetylglucosaminidase, inducing accumulation of partially degraded heparan sulfate (HS) oligosaccharides in tissues. In the central nervous system, this accumulation is associated with microglial activation, neurodegeneration, and oxidative stress. We have already shown that HS activates microglial cells through toll-like receptor 4 (TLR4) and triggers neuroinflammation. The present study investigates whether oxidative stress is a direct consequence of inflammation or is an independent event directly caused by HS accumulation. The present study addresses causative links between oxidative stress and inflammation by analyzing the corresponding markers in the cortex of control mice, MPSIIIB mice (with neuroinflammation), and double mutant TLR4 knockout MPSIIIB mice (without neuroinflammation at early stages). Results showed that, although inflammation was not present in the cortex of 10-day-old double mutant MPSIIIB/TLR4(-/-) mice, the enzymatic activity of total superoxide dismutase (SOD) was already greater than in control animals. Moreover, at 3 and 8 months of age, the total enzymatic activities of glutathione peroxidase, SOD, and carbonyl protein levels in the cortex of MPSIIIB/TLR4(-/-) mice were similar to those measured in MPSIIIB mice and were higher than those in controls. The results indicate that the oxidative stress present at a very early stage in the brain of MPSIIIB mice is not the consequence of neuroinflammation. Insofar as it has an impact on the development of neurological disease, reducing oxidative stress might prevent or slow the progression of MPSIIIB.
Collapse
Affiliation(s)
- Stéphanie Trudel
- Laboratoire d'Oncobiologie Moléculaire, Centre de Biologie Humaine, CHU Amiens Picardie, Amiens, France; EA 4666 Lymphocyte Normal et Pathologique et Cancer, Université de Picardie Jules Verne, Amiens, France
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Morlière P, Hug GL, Patterson LK, Mazière JC, Ausseil J, Dupas JL, Ducroix JP, Santus R, Filipe P. Chemistry of free radicals produced by oxidation of endogenous α-aminoketones. A study of 5-aminolevulinic acid and α-aminoacetone by fast kinetics spectroscopy. Biochim Biophys Acta Gen Subj 2014; 1840:3190-7. [PMID: 25018004 DOI: 10.1016/j.bbagen.2014.07.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2014] [Revised: 06/24/2014] [Accepted: 07/02/2014] [Indexed: 10/25/2022]
Abstract
BACKGROUND Excess 5-aminolevulinic acid (ALA) and α-aminoacetone (AA) are implicated in ketosis, porphyrinpathies and diabetes. Pathologic manifestations involve O₂⁻, H₂O₂, OH, enoyl radicals (ALA and AA) and their oxidation end products. METHODS To characterize enoyl radicals resulting from reaction of OH radicals with ALA and AA, micromolar OH concentrations were produced by pulse radiolysis of ALA and AA in aqueous solutions. RESULTS ALA and AA react with OH at k=1.5 × 10⁹ M⁻¹s⁻¹. At pH7.4, the ALA absorbance spectrum has a maximum at 330 nm (ε=750 M⁻¹cm⁻¹). This band appears as a shoulder at pH8.3 where two ALA species are present: (NH3)⁺-CH₂-CO-CH₂-CH₂-COO⁻ and NH₂-CH₂-CO-CH₂-CH₂-COO⁻ (pKa=8.3). At pH8.3, ALA reacts with oxygen (k=1.4 × 10⁸ M⁻¹s⁻¹) but not with O₂⁻. At pH8.3, AA oxidation produces two AA species characterized by an absorbance spectrum with maxima at 330 and 450 nm. ALA and AA are repaired by antioxidants (quercetin (QH), catechin, trolox, ascorbate) which are semi-oxidized (k>10(8)M⁻¹s⁻¹). QH bound to HSA or to apoferritin and ferritin repairs ALA and AA. In O₂-saturated apoferritin solutions, Q, O₂⁻, AA and reaction product(s) react with QH. CONCLUSIONS The optical absorption properties and the time evolution of ALA and AA were established for the first time. These radicals and their reaction products may be neutralized by antioxidants free in solution or bound to proteins. GENERAL SIGNIFICANCE Adjuvant antioxidant administration may be of interest in pathologies related to excess ALA or AA production.
Collapse
Affiliation(s)
- P Morlière
- INSERM, U1088, 80054 Amiens, France; CHU Amiens, Pôle Biologie, Pharmacie et Santé des Populations, Centre de Biologie Humaine, Laboratoire de Biochimie, 80054 Amiens, France; Université de Picardie Jules Verne, UFR de Pharmacie, 80036 Amiens, France.
| | - G L Hug
- University of Notre Dame, Radiation Laboratory, Notre Dame, IN 46556, USA
| | - L K Patterson
- CHU Amiens, Pôle Biologie, Pharmacie et Santé des Populations, Centre de Biologie Humaine, Laboratoire de Biochimie, 80054 Amiens, France; University of Notre Dame, Radiation Laboratory, Notre Dame, IN 46556, USA
| | - J-C Mazière
- INSERM, U1088, 80054 Amiens, France; CHU Amiens, Pôle Biologie, Pharmacie et Santé des Populations, Centre de Biologie Humaine, Laboratoire de Biochimie, 80054 Amiens, France; Université de Picardie Jules Verne, UFR de Médecine, 80036 Amiens, France
| | - J Ausseil
- INSERM, U1088, 80054 Amiens, France; CHU Amiens, Pôle Biologie, Pharmacie et Santé des Populations, Centre de Biologie Humaine, Laboratoire de Biochimie, 80054 Amiens, France; Université de Picardie Jules Verne, UFR de Médecine, 80036 Amiens, France
| | - J-L Dupas
- Université de Picardie Jules Verne, UFR de Médecine, 80036 Amiens, France; CHU Amiens, Service d'Hépato-Gastroentérologie, 80054 Amiens, France
| | - J-P Ducroix
- Université de Picardie Jules Verne, UFR de Médecine, 80036 Amiens, France; CHU Amiens, Service de Médecine Interne et Maladies Systémiques, 80054 Amiens, France
| | - R Santus
- CHU Amiens, Pôle Biologie, Pharmacie et Santé des Populations, Centre de Biologie Humaine, Laboratoire de Biochimie, 80054 Amiens, France; Muséum National d'Histoire Naturelle, Département RDDM, 75231 Paris, France
| | - P Filipe
- Hospital de Santa Maria, Faculdade de Medicina de Lisboa, Clínica Dermatologica Universitaria and Unidade de Investigação em Dermatologia, Instituto de Medicina Molecular, 1699 Lisboa Codex, Portugal
| |
Collapse
|
25
|
|
26
|
Roy E, Bruyère J, Flamant P, Bigou S, Ausseil J, Vitry S, Heard JM. GM130 gain-of-function induces cell pathology in a model of lysosomal storage disease. Hum Mol Genet 2011; 21:1481-95. [PMID: 22156940 DOI: 10.1093/hmg/ddr584] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Cell pathology in lysosomal storage diseases is characterized by the formation of distended vacuoles with characteristics of lysosomes. Our previous studies in mucopolysaccharidosis type IIIB (MPSIIIB), a disease in which a genetic defect induces the accumulation of undigested heparan sulfate (HS) fragments, led to the hypothesis that abnormal lysosome formation was related to events occurring at the Golgi level. We reproduced the enzyme defect of MPSIIIB in HeLa cells using tetracycline-inducible expression of shRNAs directed against α-N-acetylglucosaminidase (NAGLU) and addressed this hypothesis. HeLa cells deprived of NAGLU accumulated abnormal lysosomes. The Golgi matrix protein GM130 was over-expressed. The cis- and medial-Golgi compartments were distended, elongated and formed circularized ribbons. The Golgi microtubule network was enlarged with increased amounts of AKAP450, a partner of GM130 controlling this network. GM130 down-regulation prevented pathology in HeLa cells deprived of NAGLU, whereas GM130 over-expression in control HeLa cells mimicked the pathology of deprived cells. We concluded that abnormal lysosomes forming in cells accumulating HS fragments were the consequence of GM130 gain-of-function and subsequent alterations of the Golgi ribbon architecture. These results indicate that GM130 functions are modulated by HS glycosaminoglycans and therefore possibly controlled by extracellular cues.
Collapse
Affiliation(s)
- Elise Roy
- Unité Rétrovirus et Transfert Génétique, INSERM U622, Department of Neuroscience, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris, France
| | | | | | | | | | | | | |
Collapse
|
27
|
Mazière C, Trécherel E, Ausseil J, Louandre C, Mazière JC. Oxidized low density lipoprotein induces cyclin a synthesis. Involvement of ERK, JNK and NFkappaB. Atherosclerosis 2011; 218:308-13. [DOI: 10.1016/j.atherosclerosis.2011.06.034] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/01/2010] [Revised: 06/16/2011] [Accepted: 06/16/2011] [Indexed: 01/31/2023]
|
28
|
Abstract
Muscular dystrophies (MD) are a group of genetically and phenotypically heterogeneous inherited disorders characterized by the progressive degeneration of the skeletal muscle tissue. In the last decade, a tremendous amount of studies were performed to test therapeutic strategies in animal models. Evaluation of such strategies requires the use of criteria predictive of their therapeutic relevance. Here we describe a simple, noninvasive assay to monitor muscle degenerative process. An adeno-associated vector encoding a secreted form of murine embryonic alkaline phosphatase (mSEAP) reporter gene is administrated at the time of treatment. The amount of circulating mSEAP will reflect the level of myofiber survival. We tested this assay with therapeutic gene transfer. We found a strong correlation between therapeutic gene expression/muscle disease amelioration and the circulating levels of mSEAP. The assay will be very useful for monitoring muscle cell survival after therapeutic intervention.
Collapse
Affiliation(s)
- Jérôme Poupiot
- Généthon - CNRS-UMR8587 LAMBE, 1 bis rue de l'Internationale, Evry, France
| | | | | |
Collapse
|
29
|
Ellinwood NM, Ausseil J, Desmaris N, Bigou S, Liu S, Jens JK, Snella EM, Mohammed EEA, Thomson CB, Raoul S, Joussemet B, Roux F, Chérel Y, Lajat Y, Piraud M, Benchaouir R, Hermening S, Petry H, Froissart R, Tardieu M, Ciron C, Moullier P, Parkes J, Kline KL, Maire I, Vanier MT, Heard JM, Colle MA. Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. Mol Ther 2010; 19:251-9. [PMID: 21139569 DOI: 10.1038/mt.2010.265] [Citation(s) in RCA: 116] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Recent trials in patients with neurodegenerative diseases documented the safety of gene therapy based on adeno-associated virus (AAV) vectors deposited into the brain. Inborn errors of the metabolism are the most frequent causes of neurodegeneration in pre-adulthood. In Sanfilippo syndrome, a lysosomal storage disease in which heparan sulfate oligosaccharides accumulate, the onset of clinical manifestation is before 5 years. Studies in the mouse model showed that gene therapy providing the missing enzyme α-N-acetyl-glucosaminidase to brain cells prevents neurodegeneration and improves behavior. We now document safety and efficacy in affected dogs. Animals received eight deposits of a serotype 5 AAV vector, including vector prepared in insect Sf9 cells. As shown previously in dogs with the closely related Hurler syndrome, immunosuppression was necessary to prevent neuroinflammation and elimination of transduced cells. In immunosuppressed dogs, vector was efficiently delivered throughout the brain, induced α-N-acetyl-glucosaminidase production, cleared stored compounds and storage lesions. The suitability of the procedure for clinical application was further assessed in Hurler dogs, providing information on reproducibility, tolerance, appropriate vector type and dosage, and optimal age for treatment in a total number of 25 treated dogs. Results strongly support projects of human trials aimed at assessing this treatment in Sanfilippo syndrome.
Collapse
|
30
|
Vitry S, Bruyère J, Hocquemiller M, Bigou S, Ausseil J, Colle MA, Prévost MC, Heard JM. Storage vesicles in neurons are related to Golgi complex alterations in mucopolysaccharidosis IIIB. Am J Pathol 2010; 177:2984-99. [PMID: 21037080 DOI: 10.2353/ajpath.2010.100447] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The accumulation of intracellular storage vesicles is a hallmark of lysosomal storage diseases. Neither the identity nor origin of these implicated storage vesicles have yet been established. The vesicles are often considered as lysosomes, endosomes, and/or autophagosomes that are engorged with undigested materials. Our studies in the mouse model of mucopolysaccharidosis type IIIB, a lysosomal storage disease that induces neurodegeneration, showed that large storage vesicles in cortical neurons did not receive material from either the endocytic or autophagy pathway, which functioned normally. Storage vesicles expressed GM130, a Golgi matrix protein, which mediates vesicle tethering in both pre- and cis-Golgi compartments. However, other components of the tethering/fusion complex were not associated with GM130 on storage vesicles, likely accounting for both the resistance of the vesicles to brefeldin A and the alteration of Golgi ribbon architecture, which comprised distended cisterna connected to LAMP1-positive storage vesicles. We propose that alteration in the GM130-mediated control of vesicle trafficking in pre-Golgi and Golgi compartments affects Golgi biogenesis and gives rise to a dead-end storage compartment. Vesicle accumulation, Golgi disorganization, and alterations of other GM130 functions may account for neuron dysfunction and death.
Collapse
Affiliation(s)
- Sandrine Vitry
- Unité Rétrovirus et Transfert Génétique, INSERM U622, Department of Neuroscience, Institut Pasteur 28 rue du Dr Roux, 75015 Paris, France
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Hocquemiller M, Vitry S, Bigou S, Bruyère J, Ausseil J, Heard JM. GAP43 overexpression and enhanced neurite outgrowth in mucopolysaccharidosis type IIIB cortical neuron cultures. J Neurosci Res 2009; 88:202-13. [DOI: 10.1002/jnr.22190] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
32
|
Ausseil J, Desmaris N, Bigou S, Attali R, Corbineau S, Vitry S, Parent M, Cheillan D, Fuller M, Maire I, Vanier MT, Heard JM. Early neurodegeneration progresses independently of microglial activation by heparan sulfate in the brain of mucopolysaccharidosis IIIB mice. PLoS One 2008; 3:e2296. [PMID: 18509511 PMCID: PMC2396504 DOI: 10.1371/journal.pone.0002296] [Citation(s) in RCA: 98] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2008] [Accepted: 04/16/2008] [Indexed: 01/11/2023] Open
Abstract
Background In mucopolysaccharidosis type IIIB, a lysosomal storage disease causing early onset mental retardation in children, the production of abnormal oligosaccharidic fragments of heparan sulfate is associated with severe neuropathology and chronic brain inflammation. We addressed causative links between the biochemical, pathological and inflammatory disorders in a mouse model of this disease. Methodology/Principal Findings In cell culture, heparan sulfate oligosaccharides activated microglial cells by signaling through the Toll-like receptor 4 and the adaptor protein MyD88. CD11b positive microglial cells and three-fold increased expression of mRNAs coding for the chemokine MIP1α were observed at 10 days in the brain cortex of MPSIIIB mice, but not in MPSIIIB mice deleted for the expression of Toll-like receptor 4 or the adaptor protein MyD88, indicating early priming of microglial cells by heparan sulfate oligosaccharides in the MPSIIIB mouse brain. Whereas the onset of brain inflammation was delayed for several months in doubly mutant versus MPSIIIB mice, the onset of disease markers expression was unchanged, indicating similar progression of the neurodegenerative process in the absence of microglial cell priming by heparan sulfate oligosaccharides. In contrast to younger mice, inflammation in aged MPSIIIB mice was not affected by TLR4/MyD88 deficiency. Conclusions/Significance These results indicate priming of microglia by HS oligosaccharides through the TLR4/MyD88 pathway. Although intrinsic to the disease, this phenomenon is not a major determinant of the neurodegenerative process. Inflammation may still contribute to neurodegeneration in late stages of the disease, albeit independent of TLR4/MyD88. The results support the view that neurodegeneration is primarily cell autonomous in this pediatric disease.
Collapse
Affiliation(s)
- Jérôme Ausseil
- Unité Rétrovirus et Transfert Génétique, INSERM U622, Department of Neuroscience, Institut Pasteur, Paris, France
| | - Nathalie Desmaris
- Unité Rétrovirus et Transfert Génétique, INSERM U622, Department of Neuroscience, Institut Pasteur, Paris, France
| | - Stéphanie Bigou
- Service de Neurologie Pédiatrique, Hôpital Bicêtre, Assistance Publique/Hôpitaux de Paris, INSERM U802, 94000, le Kremlin-Bicêtre, France
| | - Ruben Attali
- Unité Rétrovirus et Transfert Génétique, INSERM U622, Department of Neuroscience, Institut Pasteur, Paris, France
| | - Sébastien Corbineau
- Unité Rétrovirus et Transfert Génétique, INSERM U622, Department of Neuroscience, Institut Pasteur, Paris, France
| | - Sandrine Vitry
- Unité Rétrovirus et Transfert Génétique, INSERM U622, Department of Neuroscience, Institut Pasteur, Paris, France
| | - Mathieu Parent
- Unité Rétrovirus et Transfert Génétique, INSERM U622, Department of Neuroscience, Institut Pasteur, Paris, France
| | | | - Maria Fuller
- Genetic Medicine, Children, Youth and Women's Health Service, North Adelaïde, Australia
| | - Irène Maire
- Groupement hospitalier est, CBPE, Bron, France
| | | | - Jean-Michel Heard
- Unité Rétrovirus et Transfert Génétique, INSERM U622, Department of Neuroscience, Institut Pasteur, Paris, France
- * E-mail:
| |
Collapse
|
33
|
Cheillan D, Malleval C, Ausseil J, Vitry S, Heard JM, Maire I, Honnorat J, Belin MF, Touret M. Abnormal expression of truncated CRMP-1 protein in the brain cortex of MPSIIIB mice. Mol Genet Metab 2008; 94:135-8. [PMID: 18325808 DOI: 10.1016/j.ymgme.2008.01.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/22/2008] [Accepted: 01/22/2008] [Indexed: 11/28/2022]
Abstract
Mucopolysaccharidosis IIIB is a lysosomal disease characterized by a severe neurological deterioration, the pathophysiological mechanisms of which are poorly understood. Recently FGF pathway was shown to be altered leading us to explore a downstream target involved in brain development: the collapsin response mediator protein-1 (CRMP-1). CRMP-1 transcript level was normal but a cleavage of CRMP-1 was observed with an abnormal expression of the truncated form until adult age. This truncated CRMP-1 protein could play a role in post-natal cortex maturation and be involved in neuronal alterations occurring in lysosomal diseases.
Collapse
Affiliation(s)
- David Cheillan
- INSERM, U842, Université de Lyon, Lyon1, UMR-S842, Faculté de Médecine Laennec, Lyon F-69372, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Ciron C, Desmaris N, Colle MA, Raoul S, Joussemet B, Vérot L, Ausseil J, Froissart R, Roux F, Chérel Y, Ferry N, Lajat Y, Schwartz B, Vanier MT, Maire I, Tardieu M, Moullier P, Heard JM. Gene therapy of the brain in the dog model of Hurler's syndrome. Ann Neurol 2006; 60:204-13. [PMID: 16718701 DOI: 10.1002/ana.20870] [Citation(s) in RCA: 86] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
OBJECTIVE A defect of the lysosomal enzyme alpha-L-iduronidase (IDUA) interrupts the degradation of glycosaminoglycans in mucopolysaccharidosis type I, causing severe neurological manifestations in children with Hurler's syndrome. Delivery of the missing enzyme through stereotactic injection of adeno-associated virus vectors coding for IDUA prevents neuropathology in affected mice. We examined the efficacy and the safety of this approach in enzyme-deficient dogs. METHODS Because deficient dogs raise antibodies against IDUA in response to infusion, intracerebral vector injections were combined with an immunosuppressive regimen. RESULTS Treatment was tolerated well. We observed broad dispersion of vector genomes in the brain of efficiently immunosuppressed dogs. The delivery of IDUA to large areas, which could encompass the entire brain, prevented glycosaminoglycan and secondary ganglioside accumulations. This condition was associated with drastic reduction of neuropathology throughout the encephalon. In contrast, vector injection combined with partial immunosuppression was associated with subacute encephalitis, production of antibodies against IDUA in brain tissues, and elimination of genetically modified cells. INTERPRETATION Gene therapy directed to the entire brain is feasible and may be beneficial to children with Hurler's syndrome. The possibility of subacute encephalitis emphasizes the importance of preventing immune response against IDUA, a problem that needs to be considered in similar therapies for other genetic defects.
Collapse
Affiliation(s)
- Carine Ciron
- Institut National de la Sante et de la Recherche Médicale U649, CHU Hôtel Dieu, Nantes, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Chen F, Vitry S, Hocquemiller M, Desmaris N, Ausseil J, Heard JM. alpha-L-Iduronidase transport in neurites. Mol Genet Metab 2006; 87:349-58. [PMID: 16439176 DOI: 10.1016/j.ymgme.2005.11.017] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/30/2005] [Revised: 11/16/2005] [Accepted: 11/17/2005] [Indexed: 11/17/2022]
Abstract
Effective therapeutic strategies for mucopolysaccharidosis type I (MPSI) rely on mannose-6-phosphate receptor-mediated uptake of extracellular alpha-l-iduronidase (IDUA), the missing lysosomal enzyme in this disease, by deficient cells. Intravenously infused recombinant human IDUA does not reach the central nervous system, whereas neuropathology and neurological manifestations are prominent in Hurler syndrome, the most severe and most frequent form of MPSI. The creation of a single intracerebral source of IDUA by gene therapy was proved efficient to deliver enzyme throughout the brain of MPSI mice. IDUA spreading far beyond areas where the enzyme was synthesized suggested transport along neuronal processes. To examine the mechanisms of IDUA spreading in the brain, we constructed a chimeric protein in which GFP is fused at the C-terminus of IDUA. The fusion protein was expressed in rat primary neurons using lentivirus vectors. Fluorescent IDUA retained full catalytic activity including on natural substrates, interacted with mannose-6-phosphate receptors and was appropriately addressed to lysosomes. Fluorescent vesicles were broadly distributed over neuronal soma and processes. Time-lapse fluorescent video-microscopy showed that 54% of fluorescent vesicles exhibited either retrograde or anterograde displacements along neurites. Most moving organelles showed complex movements with frequent direction changes and arrests. Motility depended on microtubule integrity. Efficient axono-dendritic transport of IDUA provides a rationale for gene therapy based on the release of therapeutic enzyme at discrete locations within the central nervous system of patients with severe form of MPSI.
Collapse
Affiliation(s)
- Fengtian Chen
- Unité Rétrovirus et Transfert Génétique, INSERM U622, Institut Pasteur, Paris, France
| | | | | | | | | | | |
Collapse
|
36
|
Ausseil J, Landry K, Seyrantepe V, Trudel S, Mazur A, Lapointe F, Pshezhetsky AV. An acetylated 120-kDa lysosomal transmembrane protein is absent from mucopolysaccharidosis IIIC fibroblasts: a candidate molecule for MPS IIIC. Mol Genet Metab 2006; 87:22-31. [PMID: 16293432 DOI: 10.1016/j.ymgme.2005.09.021] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/24/2005] [Revised: 09/20/2005] [Accepted: 09/22/2005] [Indexed: 11/27/2022]
Abstract
Genetic deficiency of the lysosomal enzyme, acetyl-CoA: alpha-glucosaminide N-acetyltransferase (N-acetyltransferase), which catalyses the transmembrane acetylation of heparan sulfate results in severe neurodegenerative disease, mucopolysaccharidosis IIIC. N-Acetyltransferase has never been characterized structurally and its gene has never been identified. We combined traditional methods of enzyme purification with organellar proteomics, isolating lysosomal membranes from mouse liver using differential centrifugation and osmolysis, followed by detergent extraction and purification of N-acetyltransferase by liquid chromatography. Partially purified enzyme had a molecular mass of 240 kDa and pI of 7.4 by gel filtration and chromatofocusing. Its specific activity varied with protein concentration typical of oligomeric enzymes or multienzyme complexes. Incubation of N-acetyltransferase with acetyl[14C]CoA in the absence of the acceptor of the acetyl group resulted in radioactive labeling of a 120-kDa polypeptide, suggesting that it represents a subunit containing the enzyme active site. Furthermore, following acetyl[14C]-labeling, the 120-kDa protein was present in the lysosomal membranes purified from the normal human skin fibroblasts but absent in those from the skin fibroblasts of MPS IIIC patients.
Collapse
Affiliation(s)
- Jérôme Ausseil
- Hôpital Sainte-Justine and Département de pédiatrie, Université de Montréal, Montréal, Que., Canada
| | | | | | | | | | | | | |
Collapse
|
37
|
Ausseil J, Loredo-Osti JC, Verner A, Darmond-Zwaig C, Maire I, Poorthuis B, van Diggelen OP, Hudson TJ, Fujiwara TM, Morgan K, Pshezhetsky AV. Localisation of a gene for mucopolysaccharidosis IIIC to the pericentromeric region of chromosome 8. J Med Genet 2005; 41:941-5. [PMID: 15591281 PMCID: PMC1735628 DOI: 10.1136/jmg.2004.021501] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Mucopolysaccharidosis type IIIC (MPS IIIC, or Sanfilippo syndrome C) is a rare lysosomal storage disorder caused by a deficiency of acetyl-coenzyme A:alpha-glucosaminide-N-acetyltransferase. Patients develop progressive neuropsychiatric problems, mental retardation, hearing loss, and relatively minor visceral manifestations. The pattern of transmission is consistent with an autosomal recessive mode of inheritance. The aim of this study was to find a locus for MPS IIIC using a homozygosity mapping approach. A genomewide scan was performed on DNA from 27 affected individuals and 17 of their unaffected relatives. Additional patients were recruited, and DNA was obtained from a total of 44 affected individuals and 18 unaffected family members from 31 families from 10 countries. A working candidate interval was defined by looking for excess homozygosity in patients compared with their relatives. Additional markers were genotyped in regions of interest. Linkage analysis was performed to support the informal analysis. Inspection of the genomewide scan data showed apparent excess homozygosity in patients compared with their relatives for markers on chromosome 8. Additional genotyping identified 15 consecutive markers (from D8S1051 to D8S2332) in an 8.3 cM interval for which the genotypes of affected siblings were identical in state. A maximum multipoint lod score of 10.61 was found at marker D8S519. A locus for MPS IIIC maps to an 8.3 cM (16 Mbp) interval in the pericentromeric region of chromosome 8.
Collapse
Affiliation(s)
- J Ausseil
- Hôpital Sainte-Justine and Département de Pédiatrie, Université de Montréal, Montréal, Québec, Canada
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Ausseil J, Soyer-Gobillard MO, Géraud ML, Bhaud Y, Baines I, Preston T, Moreau H. Characterization of p80, a novel nuclear and cytoplasmic protein in dinoflagellates. Protist 1999; 150:197-211. [PMID: 10505419 DOI: 10.1016/s1434-4610(99)70022-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
The presence of myosin in dinoflagellates was tested using an anti-Acanthamoeba castellanii myosin II polyclonal antibody on the heterotrophic dinoflagellate Crypthecodinium cohnii Seligo. Western blots revealed the presence of a unique band of 80 kDa in total protein extracts and after immunoprecipitation. Expression of this 80 kDa protein appeared constant during the different phases of the cell cycle. In protein extracts from various other dinoflagellates, this 80 kDa protein was detected only in the autotrophic species Prorocentrum micans Ehr. Screening of a C. cohnii cDNA expression library with this antibody revealed a cDNA coding for an amino acid sequence without homology in the databases. However, particular regions were detected: - a polyglutamine repeat domain in the N-terminal part of the protein, - four peptide sequences associated with GTP-binding sites, - a sequence with slight homology to the rod tail of Caenorhabditis elegans myosin II, -a sequence with homology to a human kinesin motor domain. Immunocytolocalization performed on C. cohnii thin sections with a polyclonal antibody raised against the recombinant protein showed p80 to be present both within the nucleus and in the cytoplasm. Labelling was widespread in the nucleoplasm and more concentrated at the periphery of the permanently condensed chromosomes. In the cytoplasm, labelling appeared in a punctate region close to the nucleus and in the flagellum. Potential functions of this novel protein are discussed.
Collapse
Affiliation(s)
- J Ausseil
- Observatoire Océanologique de Banyulus sur mer, Université Paris 6, Laboratoire Arago, UMR-CNRS 7628, Banyuls sur mer, France.
| | | | | | | | | | | | | |
Collapse
|
39
|
Abstract
Nuclei of the dinoflagellate Crypthecodinium cohnii strain Whd were isolated and nuclear proteins were extracted in three fractions, corresponding to the increasing affinity of these proteins to genomic DNA. One fraction contained two major bands (48- and 46-kDa) and antibodies specific to this fraction revealed two major bands by Western blot on nuclear extracts, corresponding to the 46- and 48-kDa bands. The 48-kDa protein was detected in G1 phase but not in M phase cells. An expression cDNA library of C. cohnii was screened with these antibodies, and two different open reading frames were isolated. Dinoflagellate nuclear associated protein (Dinap1), one of these coding sequences, was produced in E. coli and appeared to correspond to the 48-kDa nuclear protein. No homologue of this sequence was found in the data bases, but two regions were identified, one including two putative zinc finger repeats, and one coding for two potential W/W domains. The second coding sequence showed a low similarity to non-specific sterol carrier proteins. Immunocytolocalization with specific polyclonal antibodies to recombinant Dinap1 showed that the nucleus was immunoreactive only during the G1 phase: the nucleoplasm was immunostained, while chromosome cores and nuclear envelopes were negative.
Collapse
Affiliation(s)
- Y Bhaud
- Observatoire Océanologique de Banyuls, Laboratoire Arago, UMR CNRS 7628, Banyuls-sur-Mer France
| | | | | | | | | |
Collapse
|
40
|
Abstract
Many processes, cell motility being an example, require cells to remodel the actin cytoskeleton in response to both intracellular and extracellular signals. Reorganization of the actin cytoskeleton involves the rapid disassembly and reassembly of actin filaments, a phenomenon regulated by the action of particular actin-binding proteins. In recent years, an interest in studying actin regulation in unicellular organisms has arisen. Parasitic protozoan are among these organisms and studies of the cytoskeleton functions of these protozoan are relevant related to either cell biology or pathogenicity. To discuss recent data in this field, a symposium concerning "Actin and actin-binding proteins in protists" was held on May 8-11 in Paris, France, during the XXXV meeting of the French Society of Protistology. As a brief summary of the symposium we report here findings concerning the in vitro actin dynamic assembly, as well as the characterization of several actin-binding proteins from the parasitic protozoan Entamoeba histolytica, Trichomonas vaginalis and Plasmodium knowlesi. In addition, localization of actin in non-pathogen protists such as Prorocentrum micans and Crypthecodinium cohnii is also presented. The data show that some actin-binding proteins facilitate organization of filaments into higher order structures as pseudopods, while others have regulatory functions, indicating very particular roles for actin-binding proteins. One of the proteins discussed during the symposium, the actin depolymerizing factor ADF, was shown to enhance the treadmilling rate of actin filaments. In vitro, ADF binds to the ADP-bound forms of G-actin and F-actin, thereby participating in and changing the rate of actin assembly. Biochemical approaches allowed the identification of a protein complex formed by HSP/C70-cap32-34 which might also be involved in depolymerization of F-actin in P. knowlesi. Molecular and cellular approaches were used to identify proteins such as ABP-120 and myosin IB at the leading edge of E. histolytica. ABP-120 organizes F-actin in a network and myosin IB participates in the pseudopod formation. Similar approaches using T. vaginalis resulted in the discovery of an actin-binding protein that participate in the F-actin reorganization during adhesion of parasites to target cells. This protein is homologous to alpha-actinin from other eukaryotic cells. Finally, by using cell biology approaches, F-actin was observed in the cytoplasm as well as in the nucleus of Dinoflagellates. The recent developments in the molecular genetics of protozoa will provide new insights to understand the roles of actin-binding proteins during cytoskeleton activities.
Collapse
Affiliation(s)
- N Guillén
- Unité de Pathogénie Microbienne Moléculaire, INSERM U389, Institut Pasteur, Paris.
| | | | | | | | | |
Collapse
|
41
|
Anthony P, Ausseil J, Bechler B, Benguría A, Blackhall N, Briarty LG, Cogoli A, Davey MR, Garesse R, Hager R, Loddenkemper R, Marchant R, Marco R, Marthy HJ, Perry M, Power JB, Schiller P, Ugalde C, Volkmann D, Wardrop J. Preservation of viable biological samples for experiments in space laboratories. J Biotechnol 1996; 47:377-93. [PMID: 8987576 DOI: 10.1016/0168-1656(96)01363-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Standard viable preservation methods for biological samples using low temperatures have been investigated concerning their storage capabilities under higher temperature levels than usual. For a representative set of organism classes (plants, mammalian cells, arthropods and aquatic invertebrates), the minimum appropriate storage conditions have been identified by screening storage temperatures at -196 degrees, -80 degrees, -20 degrees, +4 degrees, +20 degrees/25 degrees C for periods from 2 days to 4 weeks. For storage below 0 degree C, as a typical cryopreservative, dimethylsulfoxide (DMSO) was used. For some samples, the addition of trehalose (as cryopreservative) and the use of a nitrogen atmosphere were investigated. After storage, the material was tested for vitality. The findings demonstrated that acceptable preservation can be achieved under higher storage temperatures than are typically applied. Small, dense cultured plant cells survive for 21 d when moderately cooled (+4 degrees to -20 degrees C); addition of trehalose enhances viability at -20 degrees C. For mammalian cells, the results show that human lymphocytes can be preserved for 3 d at 25 degrees C, 7 d at 4 degrees C and 28 d at -80 degrees C. Friend leukaemia virus transformed cells can be stored for 3 d at 25 degrees C, 14 d at 4 degrees C and 28 d at -80 degrees C. Hybridoma cells can be kept 7 d at 4 degrees C and 28 d at -20 degrees C or -80 degrees C. Model arthropod systems are well preserved for 2 weeks if maintained at lower temperatures that vary depending on the species and/or stage of development; e.g., 12 degrees C for Drosophila imagoes and 4-6 degrees C for Artemia nauplii. For aquatic invertebrates such as sea urchins, embryonic and larval stages can be preserved for several weeks at +6 degrees C, whereas sperm and eggs can best be stored at + 4 degrees C for up to 5 d at maximum. These results enhance the range of feasible space experiments with biological systems. Moreover, for typical terrestrial preservation methods, considerable modification potential is identified.
Collapse
Affiliation(s)
- P Anthony
- Life Science Department, University of Nottingham, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Ausseil J, Geraud ML, Moreau H, Baines I, Preston TM, Soyer-Gobillard M. MOLECULES INVOLVED IN THE MITOSIS OF DINOFLAGELLATE PROTISTS. Biol Cell 1996. [DOI: 10.1016/s0248-4900(97)86855-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|